Document:

Exclusive License Agreement

 Exhibit 10.15 
 CONFIDENTIAL TREATMENT REQUESTED 
 Exclusive License Agreement

 between 
 The Regents of the University of California 
 and 

KaloBios, Inc. 
 for 
 Anti-PcrV Antibody 

Case No. SF99-038 and SF01-043 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 Table of Contents 

 

					
	 Article No.        Title
	  	Page
			
	 1.
	    	Definitions	  	  3
	 2.
	    	Grant	  	  9
	 3.
	    	Sublicenses	  	10
	 4.
	    	License Issue Fee	  	13
	 5.
	    	Royalties	  	13
	 6.
	    	Due Diligence	  	17
	 7.
	    	Progress and Royalty Reports	  	18
	 8.
	    	Books and Records	  	20
	 9.
	    	Life of the Agreement	  	21
	 10.
	    	Termination by The Regents	  	22
	 11.
	    	Termination by the Licensee	  	22
	 12.
	    	Disposition of Licensed Products and Licensed Services upon Termination or Expiration	  	22
	 13.
	    	Use of Names and Trademarks	  	23
	 14.
	    	Limited Warranty	  	24
	 15.
	    	Limitation of Liability	  	25
	 16.
	    	Patent Prosecution and Maintenance	  	25
	 17.
	    	Patent Marking	  	27
	 18.
	    	Patent Infringement	  	27
	 19.
	    	Indemnification	  	30
	 20.
	    	Notices	  	32
	 21.
	    	Assignability	  	33
	 22.
	    	Late Payments	  	33
	 23.
	    	Waiver	  	34
	 24.
	    	Governing Laws; Venue; Attorneys’ Fees	  	34
	 25.
	    	Government Approval or Registration	  	34
	 26.
	    	Compliance With Laws	  	35
	 27.
	    	Force Majeure	  	35
	 28.
	    	Confidentiality	  	36
	 29.
	    	Supply of Materials	  	38
	 30.
	    	Maintenance of Materials	  	38
	 31.
	    	Miscellaneous	  	38

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 UC Case No. SF1999-038; SF2001-043 
 Print date: April 5, 2004 
 Exclusive License Agreement 

for 
 Anti-PcrV
Antibody 
 This license agreement (“Agreement”) is entered into as of this 6th day of April, 2004 (“Effective
Date”), by and between The Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and
KaloBios, Inc. (“Licensee”), a Delaware corporation, having a principal place of business at 2462 Wyandotte, Mountain View, CA 94043. 
 Recitals 
 Whereas, certain research jointly performed at The University of
California, San Francisco (“UCSF”) and at the Medical College of Wisconsin (“MCW”) resulted in the develop of inventions characterized as “ACTIVE AND PASSIVE IMMUNIZATION WITH THE PSEUDOMONAS V ANTIGEN PROTECTS AGAINST LUNG
INJURY” and “SINGLE CHAIN ANTIBODY AGAINST PcrV” [UCSF Case Nos. SF99-038 and SF01-043 respectively and Medical College of Wisconsin Research Foundation (“MCWRF”) Case No. 1097] (“Invention”), and are useful
for treating Pseudomonas infections; 
 Whereas, the Inventions were made at the UCSF by Drs. Jeanine Wiener-Kronish, Teiji
Sawa, and James Marks, and Drs. Dara Frank, Timothy Yahr, and Robert Fritz at MCW (collectively, “Inventors”) and are claimed in Patent Rights defined below; 
 Whereas, The Regents and MCWRF entered into an Inter-Institutional Agreement effective December 23, 2003 (“Inter-Institutional”) (UC Agreement Control No. 2004-18-0030) attached as
Appendix A whereby The Regents has sole responsibility for licensing the Inventions 

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
and Patent Rights, except that MCWRF administers prosecution and maintenance of the Patent Rights on the Regents behalf; 
 Whereas, the Licensee entered into a Secrecy Agreement (“Secrecy Agreement”), effective April 21, 2003 that allowed the Licensee to evaluate its interest in taking a license to the
Invention; 
 Whereas, the Invention was made under funding provided by the National Institutes of Health. 

Whereas, under 35 U.S.C. §§§200-212, The Regents may elect to retain title to any invention (including the Invention) made
by it under United States Government funding; 
 Whereas, if The Regents elects to retain title to the Invention, then the law
requires that The Regents grant to the United States Government a nontransferable, paid-up, nonexclusive, irrevocable license to use the Invention by or on behalf of the United States Government throughout the world; 

Whereas, The Regents elected on June 9, 1997 to retain title to the Invention and granted the required license (described above) to
the United States Government; 
 Whereas, the Licensee is a “small entity” as defined in 37 CFR §1.27 and a
“small-business concern” defined in 15 U.S.C. §632; 
 Whereas, the Licensee requested certain rights from The
Regents to commercialize the Invention; 
 Whereas, The Regents wishes to respond to the request of the Licensee by granting the
following rights to the Licensee so that the products and other benefits derived from the Invention can be enjoyed by the general public; 

  
 2 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 Whereas, the scope of such rights granted by The Regents is intended to extend to the scope
of the patents and patent applications pertaining to the Invention described herein; and 
 Whereas, both parties recognize that
Earned Royalties (as defined in Paragraph 5.1) due under this Agreement will be based on the Licensee’s or a sublicensee’s last act of infringement of Valid Claims of Patent Rights within the control of the Licensee or a sublicensee,
regardless of whether the Licensee or sublicensee had control over prior infringing acts; the parties intend that Earned Royalties due under this Agreement will be calculated based on the Net Sales of the product or service resulting from the last
act of infringement of Valid Claims of Patent Rights by the Licensee and its sublicensees. 
  
 

 
 The parties agree as follows: 
 1.        Definitions 
 As used in
this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 

1.1      “Patent Rights” means the Valid Claims of the United States patents and
patent applications, corresponding foreign patents and patent applications (requested under Paragraph 16.4 herein), and any reissues, re-examinations, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but
only those Valid Claims in the continuation-in-part applications that are supported in the specification and entitled to the priority date of the parent application) based on the following patents and patent applications listed in Appendix B. This
definition of Patent Rights excludes any rights in and to New Developments. 

  
 3 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 1.2      “Property Rights” means all
personal proprietary rights of The Regents covering the tangible personal property in the Biological Material. 

1.3      “Materials” means the material listed in Appendix C. This definition
specifically excludes any rights in and to New Developments. 

1.4      “Biological Materials” means: (a) the Materials or their progeny,
offspring mutations or hybrids derived therefrom by Licensee; (b) materials contained in or produced by the Materials, including secreted or encoded products obtained by Licensee from the Materials, or fragments or derivatives thereof derived
by Licensee from Materials; or (c) any material similar to a material described in (b) above, produced by Licensee using chemical synthesis or any other method, based on use of the Materials. 

1.5      “Valid Claim” means a claim of a patent or patent application in any
country that (i) has not expired; (ii) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (iii) has not been revoked, held invalid, or otherwise declared unenforceable or not allowable by a
tribunal or patent authority of competent jurisdiction over such claim in such country from which no further appeal has or may be taken. 
 1.6      “New Developments” means inventions, or claims to inventions, which constitute advancements, developments, or improvements, whether or not patentable and
whether or not the subject of any patent application, but if patentable, are not sufficiently supported by the specification of a previously-filed patent or patent application within the Patent Rights to be entitled to the priority date of the
previously-filed patent or patent application. This definition of New Developments does not include patents and patent applications claiming inventions conceived or reduced to practice under any research agreement between Licensee and The Regents
and elected by the Licensee to be included under Patent Rights 

  
 4 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 1.7      “Licensed Product” means
all kits, compositions of matter, materials, and products the manufacture, use, Sale, offer for Sale, or import of which, but for the license granted in this Agreement, would infringe, or contributorily infringe, or actively induce the infringement
of, any Valid Claims of the Patent Rights were they issued at the time of the infringing activity in that country, or would require the performance of the Licensed Method. 

1.8      “Licensed Method” means any process or method the use or practice of
which, but for the license granted in this Agreement, would infringe, or contributorily infringe, or actively induce the infringement of, any Valid Claims of the Patent Rights were they issued at the time of the infringing activity in that country.

 1.9      “Licensed Service” means the use of Licensed Products or
Licensed Method to provide a service. 
 1.10      “Net Invoice Price”
means (a) the gross invoice price charged and (subject to applicable securities laws) any Stock Consideration Proceeds received by the Licensee or the gross invoice price charged by a sublicensee for a Licensed Product or Licensed Service, or
(b) in those instances where the Licensed Product or Licensed Service is combined in any manner with any other product or service, the average gross invoice price charged for such Licensed Product or Licensed Service when sold separately over
the relevant quarter (or, if not sold separately, the amount reasonably determined by Licensee by reasonably allocating the total amount received between the Licensed Product or Licensed Service and other matter based on the respective value and
manufacturing costs thereof), less the following items, but only to the extent that they actually pertain to the disposition of such Licensed Product or Licensed Service, and are separately identified): 

 

	 	i	 allowances actually granted to customers for rejections, returns, or prompt payment or volume discounts; 

  
 5 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

	 	ii	 freight, transport packing, or insurance charges associated with transportation; 

 

	 	iii	 taxes, including Deductible Value-Added Tax, tariffs or import/export duties based on Sales when included in the gross invoice price, but excluding
value-added taxes other than Deductible Value Added Tax or taxes assessed on income derived from Sales; “Deductible Value-Added Tax” means value-added tax only to the extent that such value-added tax is actually incurred and is not
reimbursable, refundable, or creditable under the tax authority of any country; 

  

	 	iv	 discounts or rebates paid or credited to customers, third-party payers, health-care systems, or administrators solely to promote the inclusion of
Licensed Product or Licensed Service in formulary or other comparable programs; 

  

	 	v	 wholesaler’s discounts or rebates to customers, third-party payers, health-care systems, or administrators solely to promote the inclusion of
Licensed Product or Licensed Service in formulary or other comparable programs; and 

  

	 	vi	 rebates or discounts paid or credited pursuant to applicable law. 

1.11      “Sale” means the act of selling, leasing or otherwise transferring,
providing, or furnishing for use for any consideration. Correspondingly, “Sell” means to make or cause to be made a Sale, and “Sold” means to have made or caused to be made a Sale. 

1.12      “Net Sale” means: 

 

	 	1.12.a	 except in the instances described in Subparagraphs (1.12b), (1.12c), and (1.12d) of this Paragraph, the Net Invoice Price;

  

	 	1.12.b	 for any Relationship-Influenced Sale of a Licensed Product or Licensed Service, Net Sales shall be based on the Net Invoice Price at which the
Relationship-Influenced Sale Purchaser resells such Licensed Product or Licensed Service; 

  

	 	1.12.c	 in those instances where a Licensed Product or Licensed Service is not Sold, but is otherwise exploited for consideration in a non-arms-length
transaction, the Net Sales for such Licensed Product or Licensed Service shall be the Net Invoice Price of products or services of the same or substantially similar kind and quality, Sold in similar quantities, currently being offered for Sale by
the Licensee and/or any sublicensee. Where such products or services are not currently being offered for Sale by the Licensee and/or any sublicensee, the Net Sales for a Licensed Product or

  
 6 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

	 	 
Licensed Service otherwise exploited in such a non-arms-length transaction, for the purpose of computing royalties, shall be the average Net Invoice Price at which products or services of the
same or substantially similar kind and quality, Sold in similar quantities, are then currently being offered for Sale by other manufacturers. Where such products or services are not currently Sold or offered for Sale by the Licensee or any
sublicensee, or others, then the Net Sales shall be the Licensee’s or any sublicensee’s cost of manufacture of Licensed Product or the cost of conducting the Licensed Service, determined by the Licensee’s or any sublicensee’s
customary accounting procedures, plus fifty percent (50%); 

  

	 	1.12.d	 in those instances where the Licensee or a sublicensee acquires a Licensed Product or Licensed Service and then subsequently Sells or otherwise
exploits such Licensed Product or Licensed Service, Net Sales shall mean the Net Invoice Price upon Sale or other exploitation for consideration of such Licensed Product or Licensed Service by the Licensee or the sublicensee, less any amounts paid
to The Regents on account of an earlier Sale or other exploitation of such Licensed Product or Licensed Service, if any. For avoidance of doubt, end user purchasers and distributors (to the extent that distribution is the sole use of such Licensed
Products and/or Licensed Services by said distributors) of Licensed Products or Licensed Services are not sublicensees. 

 1.13    “Relationship-Influenced Sale” means a Sale of a Licensed Product or Licensed Service, or any exploitation of the Licensed Product or Licensed Method in exchange for
consideration, between the Licensee or any sublicensee and (i) an Affiliate; or (ii) a Joint Venture. 

1.14    “Relationship-Influenced Sale Purchaser” means the purchaser of Licensed Product or
Licensed Service in a Relationship-Influenced Sale. 
 1.15    “Affiliate” of the
Licensee means any entity which, directly or indirectly, Controls the Licensee, is Controlled by the Licensee, or is under common Control with the Licensee. “Control” means (i) having the actual, present capacity to elect a majority
of the directors of such affiliate, (ii) having the power to direct more than fifty percent (50%) of the voting rights entitled to elect directors, or (iii) in any country where the local law will not permit foreign equity
participation of a majority, ownership or control by a foreign entity, directly or 

  
 7 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
indirectly, of the maximum percentage of such outstanding stock or voting rights permitted by local law, provided such ownership provides such foreign entity actual, effective control of the
management and policies of the other entity. 
 1.16    “Joint Venture” means any
separate entity established pursuant to an agreement between a third party and the Licensee and/or sublicensee to constitute a vehicle for a joint venture and that Licensee Controls, in which the separate entity manufactures, uses, purchases, Sells,
or acquires Licensed Products or Licensed Services from the Licensee. 

1.17    “Field” means the antibody based diagnosis, treatment and/or prophylaxis of
Pseudomonas infection using therapeutic PcrV binding ligands. 

1.18    “Know-How” means all know-how, trade secrets, data, processes, procedures, methods,
formulas, protocols and information, existing as of the Effective Date, and developed by Drs. Jeanine Wiener-Kronish, Teiji Sawa and James Marks, and individuals working under their direct supervision who have an obligation to assign all their
rights, title and interest to The Regents, which are not covered by Patent Rights, which are necessary or useful for commercial exploitation of Patent Rights in the Field of Use. This definition of Know How excludes any rights in and to New
Developments. 
 1.19    “Stock Consideration Proceeds” shall mean cash amounts
received by Licensee from the ultimate sale by Licensee of third party stock that was granted to Licensee as consideration in a relevant transaction. For avoidance of doubt, Licensee will not accrue any liability, nor owe The Regents any amounts (as
royalties, sublicense consideration or otherwise), with respect to any stock received by Licensee as consideration in a relevant transaction, unless and until such stock is sold and Licensee receives cash therefor. 

  
 8 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 2.        Grant 

2.1    Subject to the terms and conditions of this Agreement, including the licenses granted to the
United States Government set forth in the recitals and in Paragraph 2.4 and the rights reserved in Paragraph 2.5, The Regents hereby grants to the Licensee exclusive licenses in the Field under Patent Rights to make, use, Sell, offer for Sale, and
import Licensed Products and Licensed Services and to practice the Licensed Methods in the United States and in all other countries covered by the Patent Rights. 

2.2    Subject to the terms and conditions of this Agreement, including the licenses granted to the
United States Government set forth in the recitals and in Paragraph 2.4 and the rights reserved in Paragraph 2.5, The Regents hereby grants to the Licensee an exclusive, worldwide license under Know-How in the Field. 

2.3    Subject to the terms and conditions of this Agreement, including the licenses granted to the
United States Government as set forth in the recitals and in Paragraph 2.4 and the rights reserved in Paragraph 2.5, The Regents hereby grants to the Licensee exclusive licenses under the Property Rights in the Field to possess, make (propagate),
and use Biological Materials in the United States and in all other countries where The Regents possess such Property Rights. 
 2.4    The licenses granted hereunder will be subject to the overriding obligations to the United States Government as set forth in 35 U.S.C. §§§200-212 and applicable
governmental implementing regulations and the obligation to report on utilization of the Invention set forth in 37 CFR §401.14(h). 
 2.5    Nothing in this Agreement will be deemed to limit the right of The Regents and MCW to publish any and all technical data resulting from any research performed by The Regents
and/or MCW relating to the Invention and to make and use the Invention, Licensed Product, and Licensed Service and to practice the Licensed Method and associated technology 

  
 9 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
and allow MCW to do so, in each case only for educational and non-commercial research purposes. For avoidance of doubt, the foregoing is not intended to limit The Regents or MCW with respect to
activities outside of the Field. 
 2.6    Because the Invention was made under funding
provided by the United States Government, Licensed Products, the Invention, and any products embodying the Invention Sold by Licensee and its sublicensees in the United States will be substantially manufactured in the United States to the extent
required by applicable law. If such manufacture is commercially unfeasible, the Regents will cooperate with Licensee to obtain a waiver from the U.S. Government. 
 3.        Sublicenses 
 3.1    The Regents also grants to the Licensee, so long as it retains exclusive rights under this Agreement, the right to issue sublicenses to Affiliates, Joint Ventures, and third
parties (“sublicensees”) to make, use, Sell, offer for Sale, and import Licensed Products and Licensed Services and to practice the Licensed Method, and under Property Rights and Know How to possess, make (propagate), have made and use
Biological Materials (with no right to sublicense such rights in Biological Materials to others) in the United States and in other countries where The Regents may lawfully grant such licenses. For the avoidance of doubt, Affiliates and Joint
Ventures shall have no licenses under the Patent Rights, Property Rights or Know How unless such Affiliates and Joint Ventures are granted a sublicense. All sublicenses will be consistent with all of the rights of, and will require the performance
of obligations that are consistent with all the obligations due to, The Regents (and, if applicable, the United States Government) other than those rights and obligations specified in Article 4 (License Issue Fee) and Paragraph 5.5 (minimum annual
royalties) that are contained in this Agreement, including, but not limited to, a provision that requires the payment of royalties to the Licensee in an amount sufficient to permit 

  
 10 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
the Licensee and its sublicensees to meet their royalty obligations to The Regents at the rates and bases set forth in Article 5 (Royalties). The Licensee will pay to The Regents a percentage
(according to the schedule in 3.1a through 3.1f below) of any cash consideration or (subject to applicable securities laws) Stock Consideration Proceeds received for the grant of rights under this Agreement under each sublicense agreement (excluding
any amounts received for bona fide research, development or manufacturing services) in addition to royalties (which are to be paid to The Regents under the provisions of Article 5 below), minimum annual royalties, and reimbursements for Patent
Prosecution Costs (specified in Paragraphs 16.5 and 16.6 below): 
  

	 	3.1.a	 Licensee shall pay to The Regents [***] for sublicenses executed where the Licensed Products do not include a PcrV Binding Ligand as defined in
Paragraph 4.1 below; 

  

	 	3.1.b	 Licensee shall pay to The Regents [***] for sublicenses executed prior to IND filing where the Licensed Products include a PcrV Binding Ligand as
defined in Paragraph 4.1 below; 

  

	 	3.1.c	 Licensee shall pay to The Regents [***] for sublicenses executed after IND filing but prior to initiation of Phase II clinical trials where the
Licensed Products include a PcrV Binding Ligand as defined in Paragraph 4.1 below; 

  

	 	3.1.d	 Licensee shall pay to The Regents [***] for sublicenses executed after initiation of Phase II clinical trials but prior to initiation of Phase III
clinical trials where the Licensed Products include a PcrV Binding Ligand as defined in Paragraph 4.1 below; 

  

	 	3.1.e	 Licensee shall pay to The Regents [***] for sublicenses executed after initiation of Phase III clinical trials but prior to FDA marketing approval
where the Licensed Products include a PcrV Binding Ligand as defined in Paragraph 4.1 below; and 

  

	 	3.1.f	 Licensee shall pay to The Regents [***] for sublicenses executed after FDA marketing approval where the Licensed Products include a PcrV Binding
Ligand as defined in Paragraph 4.1 below. 

 3.2    Both parties agree
that any milestone payments received by Licensee from a sublicensee (“Sublicensee-paid Milestone”) shall be subject to Article 3.1 above. In the event 

  
 11 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
that such a Sublicensee-paid Milestone is based on a performance milestone that is reasonably equivalent to one listed in Paragraph 5.11 (and sub-paragraphs therein) of this Agreement, Licensee
shall be entitled to credit such Sublicensee-paid Milestone against said equivalent milestone payment due to The Regents according to Paragraph 5.11 (and sub-paragraphs therein). For the avoidance of doubt, Licensee shall pay the greater of the
amount due for any milestone pursuant to Paragraph 5.11 (and sub-paragraphs therein), or pursuant to Article 3.1 (and sub-paragraphs therein). 
 3.3    For the purposes of this Agreement, the Licensee shall diligently monitor the operations of all sublicensees (sublicensed hereunder) and shall diligently enforce the terms of
its sublicense agreement against any such sublicensee that is in material breach thereof, including, in appropriate-ate circumstances, by terminating any such sublicensee that fails to cure a material breach of the sublicense agreement in accordance
with the terms thereof. 
 3.4    The Licensee will notify The Regents of each sublicense
granted hereunder and provide The Regents with a complete copy of each sublicense within thirty (30) days of issuance of the sublicense. Consideration owed to The Regents under Paragraph 3.1 above will be paid to The Regents on or before the
due date of the royalty report applicable to the quarter in which consideration was received by the Licensee under the sublicense. The Licensee will collect from the sublicensees and pay to The Regents all fees, royalties and cash due The Regents as
set forth in Paragraphs 3.1 and 5.1. The Licensee will guarantee all monies due The Regents from the sublicensees. The Licensee will require sublicensees to provide it with copies of all Progress Reports and royalty reports in accordance with the
provisions herein, and the Licensee will collect and deliver to The Regents all such reports due from sublicensees. 

  
 12 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 3.5    Upon termination of this Agreement for any
reason, The Regents, at its sole discretion, will determine whether any or all sublicenses will be canceled or assigned to The Regents (but only to the extent related to rights granted hereunder). 

4.        License Issue Fee 

4.1    As partial consideration for all the rights and licenses granted to the Licensee, the Licensee
will pay to The Regents a license issue fee of Twenty Five Thousand Dollars ($25,000) within thirty (30) days after the identification of a PcrV Binding Ligand, where “PcrV Binding Ligand” means an anti-PcrV antibody molecule derived
from the KaloBios technology platform that has activity in a rodent survival model equivalent to or better than mAb166. 
 4.2    The Licensee will also pay to The Regents a license maintenance fee of [***] on the one (1)-year anniversary date of the Effective Date and on each anniversary of the Effective
Date thereafter. Notwithstanding the foregoing, the license maintenance fee will not be due and payable on any anniversary of the Effective Date after the date Licensee begins Selling or otherwise exploiting Licensed Products or Licensed Services,
and owes its first Earned Royalty (as defined below) to The Regents on the Net Sales of such Licensed Products or Licensed Services. 
 4.3    The fees set forth in Paragraphs 4.1 and 4.2 above are not refundable, not creditable, and not an advance against any fees, royalties, other monies, or reimbursement of Patent
Prosecution Costs required to be paid under the terms of this Agreement. 

5.        Royalties 

5.1    As further consideration for all the rights and licenses granted to the Licensee, the Licensee
will pay to The Regents an earned royalty at the rate of three percent (3%) based on the Net Sales of Licensed Product and Licensed Services (“Earned Royalty”). 

  
 13 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 5.2    Earned Royalties will accrue in each country for
the duration of Patent Rights in that country and will be payable to The Regents quarterly (as described below) when revenue for Licensed Products or Licensed Services is received by the Licensee or a sublicensee in a manner constituting a Net Sale
as defined in Paragraph 1.12. 
 5.3    Earned Royalties and other consideration payable to
The Regents will be paid quarterly on or before the following dates of each calendar year: 
  

	 	•	 	 February 28 for the calendar quarter ending December 31; 

 

	 	•	 	 May 31 for the calendar quarter ending March 31; 

 

	 	•	 	 August 31 for the calendar quarter ending June 30; and 

 

	 	•	 	 November 30 for the calendar quarter ending September 30. 

5.4    Each such payment will be for royalties which accrued up to the last day of the most recently
completed calendar quarter. 
 5.5    Beginning in the first year an Earned Royalty is due
to The Regents and in each succeeding calendar year thereafter the Licensee will pay to The Regents a minimum annual royalty [***]. This minimum annual royalty will be paid to The Regents by February 28 of each year and will be credited against
the Earned Royalty due and owing for the calendar year in which the minimum payment was made. 

5.6    All consideration due The Regents will be payable in United States dollars. When Licensed
Products or Licensed Services are Sold for monies other than United States dollars, the Earned Royalties and any other consideration due to The Regents will first be determined in the foreign currency of the country in which such Licensed Products
or Licensed Services were Sold or other consideration was received and then converted into equivalent United States dollars. The exchange rate will be the average exchange rate quoted in the Wall Street Journal during the last thirty (30) days
of the reporting period. 

  
 14 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 5.7    Earned Royalties on Net Sales of Licensed
Products or Licensed Services occurring in and any other consideration received in any country outside the United States will not be reduced by any taxes, fees, or other charges imposed by the government of such country except those taxes, fees, and
charges allowed under the provisions of Paragraph 1.12 (Net Sales). The Licensee also will be responsible for all bank transfer charges. 
 5.8    Notwithstanding the provisions of Article 27 (Force Majeure), if at any time legal restrictions prevent prompt remittance of any Earned Royalties or other consideration owed to
The Regents by the Licensee with respect to any country where a sublicense is issued or a Licensed Product or Licensed Service is Sold or otherwise exploited, then the Licensee will convert the amount owed to The Regents into United States dollars
and will pay The Regents directly from another source of funds in order to remit the entire amount owed to The Regents. 
 5.9    In the event that any patent or any claim thereof included within the Patent Rights is held invalid in a final decision by a court of competent jurisdiction and last resort and
from which no appeal has or can be taken, all obligation to pay royalties based on such patent or claim or any claim patentably indistinct therefrom will cease as of the date of such final decision. The Licensee will not, however, be relieved from
paying any royalties that accrued before such final decision, and the Licensee shall be obligated to pay the full amount of royalties due hereunder to the extent that The Regents licenses one or more Valid Claims within the Patent Rights to the
Licensee with respect to Licensed Products or Licensed Services sold by Licensee or a sublicensee. 

5.10    No Earned Royalties as provided in Paragraph 5.1 will be collected or paid hereunder to The
Regents on Licensed Products or Licensed Services Sold to, or otherwise exploited for, the account of the United States Government. The Licensee and its sublicensee 

  
 15 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
will reduce the amount charged for Licensed Products or Licensed Services Sold to, or otherwise exploited by, the United States Government by an amount equal to the Earned Royalty for such
Licensed Products or Licensed Services otherwise due The Regents. 
 5.11    Licensee will
also pay a non-refundable, non-creditable earned royalty to The Regents in the form of milestone payments according to the following schedule: 
  

	 	5.11.a	 Licensee shall pay The Regents a milestone of [***] upon the first IND filing (or foreign equivalent) for a Licensed Product if such filing is made
within one (1) year of the Effective Date; or, [***] upon the first IND filing (or foreign equivalent) for a Licensed Product if such filing is made subsequent to the one (1) year anniversary of the Effective Date;

  

	 	5.11.b	 Licensee shall pay The Regents a milestone of [***] upon initiation of Phase III clinical trials (or foreign equivalent) for the first Licensed
Product; 

  

	 	5.11.c	 Licensee shall pay The Regents a milestone of [***] upon acceptance of a BLA (or foreign equivalent) for the first Licensed Product;

  

	 	5.11.d	 Licensee shall pay The Regents a milestone of [***] upon FDA marketing approval (or foreign equivalent) for the first Licensed Product.

 5.12    Each milestone listed in 5.10a through 5.10d above shall be
payable in four equal quarterly installments according to the schedule listed in Paragraph 5.3. For the avoidance of doubt, it is understood that in no event shall Licensee be obligated to make the payment due on any milestone more than once
regardless of the number of Licensed Products put into development and regardless of the number of indications for which Licensed Products are developed. 
 5.13    If it becomes necessary for Licensee to license intellectual property rights from an unaffiliated third party(ies), and Licensee is required to pay a royalty to that
unaffiliated third party in order to make, use or sell Licensed Products, and the combined earned royalty due The Regents and unaffiliated third parties exceeds [***], then the earned royalties to be paid to The Regents by Licensee shall be reduced
by a proportional amount equal to X/N, where X equals 

  
 16 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
the excess over [***] of the royalty rate(s) due to the parties, and N equals the total number of parties to which royalties are due, including The Regents. However, in no event shall the amount
paid to The Regents be reduced below fifty percent (50%) of the original earned royalty amounts due The Regents. 

6.        Due Diligence 

6.1    The Licensee, upon execution of this Agreement, will diligently proceed with the development,
manufacture, and Sale of Licensed Products and Licensed Services and will earnestly and diligently market the same after execution of this Agreement using commercially reasonable efforts to generally meet the market demands therefor, using resources
comparable to other products of similar market potential in Licensee’s product portfolio. 

6.2    The Licensee will obtain all necessary governmental approvals in each country where Licensed
Products and Licensed Services are manufactured, used, Sold, imported, or offered for Sale. 

6.3    If the Licensee does not use commercially reasonable efforts to perform any of the following:

  

	 	6.3.a	 submit an IND covering Licensed Products and/or Licensed Services to the United States FDA within three (3) years after the Effective Date;

  

	 	6.3.b	 market Licensed Products and/or Licensed Services in the United States within [***] of receiving approval of such Licensed Products or Licensed
Services from the United States FDA; 

 then, subject to equitable extensions reasonably agreed upon by The Regents and
Licensee, The Regents will have the right and option to terminate this Agreement or reduce the exclusive licenses granted to the Licensee to non-exclusive licenses in accordance with Paragraph 6.4 below. 

  
 17 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 6.4    To exercise either the right to terminate this
Agreement or to reduce the exclusive licenses granted to the Licensee to non-exclusive licenses for lack of diligence required in this Article 6 (Due Diligence), The Regents will give the Licensee written notice of the deficiency. The Licensee
thereafter has ninety (90) days to cure the deficiency. If The Regents has not received written tangible evidence satisfactory to The Regents that the deficiency has been cured or that a plan, acceptable to The Regents, is in place to make cure
by the end of the ninety (90) day period, then The Regents may, at its option, terminate this Agreement immediately without the obligation to provide 60 days’ notice as set forth in Paragraph 10.1 or reduce the exclusive licenses granted
to the Licensee to non-exclusive licenses by giving written notice to the Licensee. 

7.        Progress and Royalty Reports 

7.1    Beginning on August 31, 2004, and semi-annually thereafter, the Licensee will submit to
The Regents a progress report as described in Paragraph 7.2 below covering activities by the Licensee and its sublicensees related to the development and testing of all Licensed Products and Licensed Services and the obtaining of any governmental
approvals required for marketing them (“Progress Report”) until the first Sale or other exploitation of each Licensed Product and Licensed Service in the United States. For the avoidance of doubt, failure to submit a timely Progress Report
to The Regents shall constitute a material breach of this Agreement (subject to cure under Section 10.1). If either party terminates this Agreement before any Licensed Products or Licensed Services are Sold or before this Agreement’s
expiration, a final Progress Report covering the period prior to termination must be submitted within thirty (30) days of termination. 
 7.2    The Progress Reports submitted under Paragraph 7.1 above will include, but not be limited to, a detailed summary of the following topics so that The Regents will be able to

  
 18 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
determine the progress of the development of Licensed Products and Licensed Services and will also be able to determine whether or not the Licensee has met its diligence obligations set forth in
Article 6 (Due Diligence) above: 
  

	 	•	 	 summary of work completed as of the submission date of the Progress Report; 

 

	 	•	 	 key scientific discoveries as of the submission date of the Progress Report; 

 

	 	•	 	 summary of work in progress as of the submission date of the Progress Report; 

 

	 	•	 	 current schedule of anticipated events and milestones, including those events and milestones specified under Paragraph 6.3 above;

  

	 	•	 	 anticipated and actual market introduction dates of each Licensed Product and Licensed Service; and 

 

	 	•	 	 activities of the sublicensees, if any. 

 7.3    The Licensee also will report to The Regents in its immediately subsequent Progress Report the date of first Sale or other exploitation of a Licensed Product or Licensed Service
in each country. 
 7.4    After the first Sale or other exploitation of a Licensed Product
or Licensed Service, the Licensee will provide quarterly royalty reports to The Regents on or before each February 28, May 31, August 31, and November 30 of each year. Each such royalty report will cover the most
recently completed calendar quarter (October through December, January through March, April through June, and July through September) and will show: 
  

	 	7.4.a	 the gross invoice prices and Net Sales of Licensed Products and Licensed Services Sold or otherwise exploited in exchange for consideration by the
Licensee and its sublicensees during the most recently completed calendar quarter; 

  

	 	7.4.b	 the quantity of Licensed Products and Licensed Services Sold or otherwise exploited in exchange for consideration by the Licensee and its
sublicensees during the most recently completed calendar quarter; 

  

	 	7.4.c	 the Earned Royalties, in United States dollars, payable hereunder with respect to Net Sales; 

  
 19 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

	 	7.4.d	 the method used to calculate the royalty, specifying all deductions taken and the dollar amount of each such deduction; and

  

	 	7.4.e	 the exchange rates used, if any. 

 7.5    If no Sales of Licensed Products and Licensed Services have been made and no Licensed Products and Licensed Services have been otherwise exploited in exchange for consideration
during any reporting period after the first Sale of a Licensed Product or Licensed Service, then a statement to this effect must be provided by the Licensee in the immediately subsequent royalty report. 

8.        Books and Records 

8.1    The Licensee will keep books and records accurately showing all payments due The Regents and
all Licensed Products and Licensed Services manufactured, used, offered for Sale, imported, Sold, and/or otherwise exploited under the terms of this Agreement. Subject to Section 28, such books and records will be preserved for at least five
(5) years after the date of the payment to which they pertain and will be open to inspection by a nationally recognized independent accounting firm designated by The Regents at reasonable times (but no more than once a year) to determine their
accuracy and assess the Licensee’s compliance with the terms of this Agreement. 

8.2    The fees and expenses of representatives of The Regents performing such an examination will be
borne by The Regents. If, however, an error in royalties of more than five percent (5%) of the total royalties due for any year is discovered the Licensee shall bear the cost of the examination. The Licensee shall remit any underpayment to The
Regents within thirty (30) days of the examination result. 

  
 20 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 9.        Life of the Agreement 

9.1    Unless otherwise terminated by operation of law, Paragraph 9.2, or by acts of the parties in
accordance with the terms of this Agreement, this Agreement will remain in effect from the Effective Date until the expiration, invalidation or abandonment of the last of the Patent Rights licensed hereunder. 

9.2    This Agreement shall automatically terminate without the obligation to provide 60 days’
notice as set forth in Paragraph 10.1 upon the filing of a petition for relief under the United States Bankruptcy Code by or against the Licensee as a debtor or alleged debtor if such petition is not dismissed within 60 days. 

9.3    Any termination or expiration of this Agreement will not affect the rights and obligations set
forth in the following Articles: 
  

					
	 Article 1
	 	 Definitions
	 	
			
	 Paragraph 2.2
	 	 Know How License
	 	
			
	 Paragraphs 5.1 and 5.2 (only to the extent
          accrued prior to the date of
termination)
	 	 Royalties
	 	
			
	 Article 8
	 	 Books and Records
	 	
			
	 Article 9
	 	 Life of the Agreement
	 	
			
	 Article 12
	 	 Disposition of Licensed Products and
          Licensed Services upon Termination
or
          Expiration
	 	
			
	 Article 13
	 	 Use of Names and Trademarks
	 	
			
	 Article 14
	 	 Limited Warranty
	 	
			
	 Article 15
	 	 Limitation of Liability
	 	
			
	 Paragraphs 16.5 (only to the extent accrued
          prior to the date of termination) and
16.6
          (subject to the limitations therein)
	 	 Patent Prosecution and Maintenance
	 	
			
	 Article 19
	 	 Indemnification
	 	
			
	 Article 20
	 	 Notices
	 	
			
	 Article 22
	 	 Late Payments
	 	
			
	 Article 24
	 	 Governing Laws; Venue; Attorneys’ Fees
	 	

  
 21 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

					
			
	 Article 28
	  	 Confidentiality
	  	

 9.4    The termination or expiration of this Agreement will not
relieve the Licensee of its obligation to pay any fees, royalties, reimbursements for Patent Prosecution Costs, or other payments owed to The Regents prior to the date of such termination or expiration and will not impair any accrued right of The
Regents, including the right to receive Earned Royalties in accordance with Articles 5 and 12 and the right to receive Stock Consideration Proceeds in accordance with Article 3. 

10.      Termination by The Regents 

10.1    If the Licensee should materially breach this Agreement, then The Regents may give written
notice of such default (“Notice of Default”) to the Licensee. If the Licensee should fail to repair such default within sixty (60) days after the date such notice takes effect, The Regents will have the right to immediately terminate
this Agreement and the licenses hereunder by providing a written notice of termination (“Notice of Termination”) to the Licensee. 
 11.      Termination by the Licensee 
 11.1    The Licensee will have the right at any time to terminate this Agreement by providing a Notice of Termination to The Regents. Moreover, the Licensee will be entitled to
terminate the rights under Patent Rights on a country-by-country basis by giving notice in writing to The Regents. Termination of this Agreement (but not termination of any patents or patent applications under Patent Rights, which termination is
subject to Paragraph 16.6) will be effective sixty (60) days after the date such notice takes effect. 

12.      Disposition of Licensed Products and Licensed Services upon Termination or Expiration

 12.1    Upon termination of this Agreement, within a period of one hundred and twenty
(120) days after the date of termination, the Licensee may (a) complete any partially made 

  
 22 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
Licensed Products and continue to render any previously commenced Licensed Services and (b) Sell all previously made or partially made Licensed Products, provided, however, that the Sale of
such Licensed Products and Licensed Services will be subject to the terms of this Agreement including, but not limited to, the payment of Earned Royalties at the times provided herein and the rendering of royalty reports in connection therewith. The
Licensee may not otherwise make, Sell, offer for Sale, or import Licensed Products or Licensed Services, or practice the Licensed Method after the date of termination. 

12.2    If applicable Patent Rights existed at the time of any making, Sale, offer for Sale, or
import of a Licensed Product or at the time of any Sale, offer for Sale, or rendering of a Licensed Service, then Earned Royalties shall be paid at the times provided herein and royalty reports shall be rendered in connection therewith,
notwithstanding the absence of applicable Patent Rights with respect to such Licensed Product or Licensed Service at any later time. Otherwise, no Earned Royalties shall be paid on such product or service. 

13.      Use of Names and Trademarks 

13.1    Nothing contained in this Agreement will be construed as conferring any right to either party
to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of the other party (including a contraction, abbreviation or simulation of any of the foregoing). The use by the Licensee of the
name “Medical College of Wisconsin Research Foundation” or the name of any campus of The Medical College of Wisconsin in advertising, publicity, or other promotional activities is expressly prohibited, except as required by law in
connection with a public offering. Unless consented to in writing by the Executive Director, Office of Technology Transfer of The Regents, the use by the Licensee of the name “The Regents of the University of California” or the name of any
campus of the 

  
 23 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
University of California in advertising, publicity, or other promotional activities is expressly prohibited, except as required by law in connection with a public offering. 

14.      Limited Warranty 

14.1    The Regents warrants to the Licensee that it has the lawful right to grant this license.

 14.2    Except as expressly set forth in this Agreement, the licenses and the associated
Invention, Patent Rights, Property Rights, Know-How, Licensed Products, Licensed Services, and Licensed Methods are provided by The Regents WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND,
EITHER EXPRESS OR IMPLIED. THE REGENTS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE INVENTION, PATENT RIGHTS, PROPERTY RIGHTS, KNOW-HOW, LICENSED PRODUCTS, LICENSED SERVICES, OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK OR OTHER RIGHTS. 
 14.3    Nothing in this Agreement is or shall be
construed as: 
  

	 	14.3.a	 a warranty or representation by The Regents as to the validity, enforceability, or scope of any Patent Rights; or 

 

	 	14.3.b	 a warranty or representation that anything made, used, Sold, or otherwise exploited under any license granted in this Agreement is or will be free
from infringement of patents, copyrights, or other rights of third parties; or 

  

	 	14.3.c	 an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 18 (Patent
Infringement); or 

  

	 	14.3.d	 conferring by implication, estoppel, or otherwise any license or rights under any patents or other rights of The Regents and/or MCWRF other than
Patent Rights, Property Rights and Know-How, regardless of whether such patents are dominant or subordinate to Patent Rights; or 

  
 24 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

	 	14.3.e	 an obligation to furnish any New Developments, know-how, technology, or technological information not provided in Patent Rights, Property Rights, or
Know-How. 

 15.      Limitation of Liability 

15.1     THE REGENTS WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE
GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING
OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF THE REGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

16.      Patent Prosecution and Maintenance 

16.1     Pursuant to the Inter-institutional, all actions by The Regents in this Article 16
shall be made through MCWRF. For the avoidance of doubt, any payments due from Licensee under Paragraphs 16.5 and/or 16.6 below shall be paid to MCWRF at the address indicated in Article 20. 

16.2     The Regents will diligently prosecute and maintain the United States and foreign
patents comprising the Patent Rights using counsel of its choice who will take instructions solely from The Regents. The Regents will promptly provide the Licensee with copies of all relevant documentation so that the Licensee will be informed and
apprised of the continuing prosecution and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response, provided, however, that if the Licensee has not commented upon such documentation in reasonable
time for The Regents to sufficiently consider the Licensee’s 

  
 25 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
comments prior to a deadline with the relevant government patent office, or The Regents must act to preserve Patent Rights, The Regents will be free to respond without consideration of the
Licensee’s comments, if any. 
 16.3     The Regents will use reasonable efforts
to amend any patent application to include claims requested by the Licensee and required to protect the Licensed Products or Licensed Services contemplated to be Sold, or the Licensed Method to be practiced, under this Agreement. 

16.4     The Regents will, at the Licensee’s request, file, prosecute, and maintain patent
applications and patents included under Patent Rights in foreign countries, if available. The Licensee must notify The Regents within seven (7) months of the filing of the corresponding United States patent application of its request for The
Regents to file foreign counterpart patent applications. This notice concerning foreign filing must be in writing and must identify the countries desired. The absence of such a notice from the Licensee to The Regents within the seven (7)-month
period will be considered an election by the Licensee not to request The Regents to secure foreign Patent Rights on its behalf. The Regents will have the right to file patent applications at its own expense in any country the Licensee has not
included in its list of desired countries, and such patent applications and resultant patents, if any, will not be included in the licenses granted hereunder, provided Licensee has not elected to pay for such applications within 30 days of notice
from The Regents of its desire to proceed in any such country. 
 16.5     All costs of
obtaining patentability opinions (if required), preparing, filing, prosecuting in whatsoever manner, and maintaining all United States and corresponding foreign patent applications and resulting patents specified under Patent Rights (“Patent
Prosecution Costs”) will be borne by the Licensee, including, but not limited to, Patent Prosecution Costs 

  
 26 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
incurred by The Regents and MCWRF prior to the execution of this Agreement, totaling approximately $20,795.45. The costs of all interferences, oppositions, reexaminations, and reissues shall be
deemed to be Patent Prosecution Costs and also will be borne by the Licensee. The Licensee will reimburse The Regents for all Patent Prosecution Costs within thirty (30) days following receipt of an itemized invoice from The Regents for Patent
Prosecution Costs. 
 16.6     The Licensee will pay any Patent Prosecution Costs
incurred during the three (3)-month period after receipt by either party of a Notice of Termination, even if the invoices for such Patent Prosecution Costs are received by The Regents after the end of the three (3)-month period following receipt of
a Notice of Termination. The Licensee may terminate its obligation to pay Patent Prosecution Costs with respect to any particular patent application or patent under Patent Rights in any or all designated countries upon three (3)-months’ written
notice to The Regents. The Regents may continue prosecution and/or maintenance of such patent application or patent at its sole discretion and expense, provided, however, that the Licensee will have no further rights or licenses thereunder.

 16.7     The Licensee will notify The Regents of any change of its status as a small
entity (as defined by the United States Patent and Trademark Office) and of the first sublicense granted to an entity that does not qualify as a small entity. 
 17.      Patent Marking 

17.1     The Licensee will mark all Licensed Products made, used, or Sold under the terms of
this Agreement or their containers in accordance with the applicable patent marking laws. 

18.      Patent Infringement 

18.1     In the event that The Regents (to the extent of the actual knowledge of the licensing
professional responsible for the administration of this Agreement) or the Licensee learns of infringement of potential commercial significance of any patent licensed under this 

  
 27 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence of such infringement available to it (the
“Infringement Notice”). During the period in which, and in the jurisdiction where, the Licensee has exclusive rights under this Agreement, neither The Regents nor the Licensee will notify a third party (including the infringer) of
infringement or put such third party on notice of the existence of any Patent Rights in an adversarial manner without first obtaining consent of the other. For the avoidance of doubt, any notice given by Licensee that expressly accuses a third party
of infringing the Patent Rights, which is knowingly given without The Regents’ consent, may constitute a material breach of this Agreement depending upon the severity of the circumstance. Both The Regents and the Licensee will use their
diligent efforts to cooperate with each other to terminate such infringement without litigation. 

18.2     If infringing activity of potential commercial significance by the infringer has not
been abated within ninety (90) days following the date the Infringement Notice takes effect (or, with The Regents’ consent, sooner in exigent circumstances), the Licensee may institute suit for patent infringement against the infringer.
The Regents may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of the Licensee’s suit or any judgment rendered in that suit. The
Regents will join in any suit initiated by the Licensee upon Licensee’s request, if such joinder is required by law for Licensee to pursue such action. If, in a suit initiated by the Licensee, The Regents is involuntarily joined other than by
the Licensee or requested to join by Licensee, the Licensee will pay any costs incurred by The Regents arising out of such suit, including but not limited to, any legal fees of counsel that The Regents selects and retains to represent it in the
suit. 

  
 28 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 18.3     If, within a hundred and twenty
(120) days following the date the Infringement Notice takes effect, infringing activity of potential commercial significance by the infringer has not been abated and if the Licensee has not brought suit against the infringer, The Regents may
institute suit for patent infringement against the infringer. If The Regents institutes such suit, the Licensee may not join such suit without The Regents’ consent and may not thereafter commence suit against the infringer for the acts of
infringement that are the subject of The Regents’ suit or any judgment rendered in that suit. 

18.4     Any recovery or settlement received in connection with any suit will first be shared by
The Regents and the Licensee equally to cover the litigation costs each incurred, and next shall be paid to The Regents or the Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other. In any suit initiated
by the Licensee, any recovery in excess of litigation costs will be shared between the Licensee and The Regents as follows: (a) for any recovery other than amounts paid for willful infringement: (i) The Regents will receive [***] of the
recovery if The Regents was not a party in the litigation and did not incur any litigation costs, (ii) The Regents will receive [***] of the recovery if The Regents was a party in the litigation, but did not incur any litigation costs,
including the provisions of Paragraph 18.2 above, and (iii) if The Regents paid its own litigation costs, The Regents will receive the percentage of the remaining recovery that corresponds to the percentage of the overall litigation costs that
The Regents paid in connection with the litigation [***]; and (b) for the portion of any recovery for willful infringement, The Regents will receive [***] of such recovery. In any suit initiated by The Regents, any recovery in excess of
litigation costs will belong to The Regents. The Regents and the Licensee agree to be bound by all determinations of patent infringement, 

  
 29 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
validity, and enforceability (but no other issue) resolved by any adjudicated judgment in a suit brought in compliance with this Article 18. 

18.5     Any agreement made by the Licensee for purposes of settling litigation or other dispute
shall comply with the requirements of Article 3 (Sublicenses) of this Agreement. 

18.6     Each party will cooperate with the other in litigation proceedings instituted hereunder
but at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties). 
 18.7     Any litigation proceedings will be controlled by the party bringing the suit, except that The Regents may be represented by counsel of its choice in any suit brought by
the Licensee. 
 19.      Indemnification 

19.1     The Licensee will, and will require its sublicensees to, indemnify, hold harmless, and
defend The Regents, MCW and their officers, employees, and agents, the sponsors of the research that led to the Invention, the inventors of any invention claimed in patents or patent applications under Patent Rights (including the Licensed Products,
Licensed Services, and Licensed Methods contemplated thereunder), and the inventors of the inventions in Property Rights or Know-How and their employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from, or
arising out of, any third party claim that arises out of the exercise of this license or any sublicense. This indemnification will include, but will not be limited to, any product liability. The Regents shall inform Licensee promptly of any such
indemnifiable claim which is brought against it and shall, at Licensee’s request, cooperate with Licensee with respect to the defense and/or settlement of such indemnifiable claim. Licensee shall have full control over the suit or proceedings,
including the right to settle, through counsel of its choice who is reasonably acceptable to Regents; provided, however, Licensee will not, 

  
 30 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
absent the consent of Regents (which consent will not be unreasonably withheld), consent to the entry of any judgment or enter into any settlement (1) where the claimant or plaintiff does
not release Regents from all liability in respect thereof, and/or (2) where any admission of wrongdoing or liability is made, or any other material negative action is required, by the Regents. If The Regents, in its reasonable discretion,
believes that there will be a conflict of interest or it will not otherwise be adequately represented by counsel chosen by the Licensee to defend The Regents in accordance with this Paragraph 19.1, then The Regents may retain counsel of its choice
to represent it, and the Licensee will pay all expenses for such representation. 

19.2     During the term of this Agreement starting prior to the commencement of human clinical
trials and for three (3) years following termination or expiration of this Agreement, the Licensee, at its sole cost and expense, will insure its activities in connection with any work performed hereunder and will obtain and maintain the
following insurance (or an equivalent program of self insurance): 
  

	 	19.2.a	 Comprehensive or Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 

 

					
	 Each Occurrence
	  	$	3,000,000	  
		
	 Products/Completed Operations Aggregate
	  	$	3,000,000	  
		
	 Personal and Advertising Injury
	  	$	3,000,000	  
		
	 General Aggregate (commercial form only)
	  	$	3,000,000	  

  

	 	19.2.b	 The coverage and limits referred to in Subparagraph (19.2a) above will not in any way limit the liability of the Licensee. The Licensee will
furnish The Regents with certificates of insurance evidencing compliance with all requirements. Such certificates will: 

  

	 	    i	 Provide for thirty (30) days’ advance written notice to The Regents of any modification; 

 

	 	    ii	 Indicate that The Regents has been endorsed as an additional insured under the coverage described above; and 

  
 31 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

	 	        iii	 Include a provision that the coverage will be primary and will not participate with, nor will be excess over, any valid and collectable insurance or
program of self-insurance maintained by The Regents. 

 19.3     The
Regents will promptly notify the Licensee in writing of any claim or suit brought against The Regents for which The Regents intends to invoke the provisions of this Article 19 (Indemnification). The Licensee will keep The Regents informed of its
defense of any claims pursuant to this Article 19 (Indemnification). 
 20.      Notices

 20.1     Any notice or payment required to be given to either party will be deemed
to have been properly given and to be effective: 
  

	 	20.1.a	 on the date of delivery if delivered in person; 

  

	 	20.1.b	 on the date of mailing if mailed by first-class certified mail, postage paid; or 

 

	 	20.1.c	 on the date of mailing if mailed by any global express carrier service that requires the recipient to sign the documents demonstrating the delivery
of such notice or payment; 

 to the respective addresses given below, or to another address as designated in
writing by the party changing its address. 
  

					
	In the case of the Licensee:	  	KaloBios Pharmaceuticals, Inc.	  	 
		  	3427 Hillview Ave
Palo Alto, CA 94304	  	
		  	Telephone: 650-843-1897	  	
		  	Facsimile: 650-843-1896	  	
		  	Attention: Mark R. Alfenito	  	

  
 32 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

					
	In the case of The Regents:	  	THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
University of California, San Francisco
Office of Technology Management
185 Berry Street Suite 4603
San
Francisco, CA 94107
Telephone  (415) 353-4463
Facsimile:  (415) 348-1579
Attention:   Director,
Referring to: UCSF Case No. SF99-038
and SF01-043
		
	In the case of patent expense reimbursements:	  	MCW Research Foundation
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
Attn: Joseph Hill, Ph.D.

 21.      Assignability 

21.1     This Agreement is personal to the Licensee. The Licensee may not assign or transfer
this Agreement, including by operation of law, or otherwise, without The Regents’ prior written consent, except to a successor to all or substantially all of Licensee’s assets or business. This Agreement is binding upon and will inure to
the benefit of The Regents, its successors and assigns. 
 22.      Late Payments

 22.1     In the event that royalties, fees, reimbursements for Patent Prosecution
Costs, or other monies owed to The Regents are not received by The Regents when due, the Licensee will pay to The Regents interest at a rate of ten percent (10%) simple interest per annum. Such interest will be calculated from the date payment
was due until actually received by The Regents. Such accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of The Regents due to such late payment. Acceptance by The Regents of any late payment from

  
 33 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
the Licensee under this Article 22 will in no way affect the provision of Article 23 (Waiver) herein. 
 23.      Waiver 

23.1     No waiver by either party of any breach or default of any of the covenants or
agreements contained herein will be deemed a waiver as to any subsequent and/or similar breach or default. No waiver will be valid or binding upon the parties unless made in writing and signed by a duly authorized officer of each party. 

24.      Governing Laws; Venue; Attorneys’ Fees 

24.1     THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
STATE OF CALIFORNIA, excluding any choice of law rules that would direct the application of the laws of another jurisdiction, but the scope and validity of any patent or patent application will be governed by the applicable laws of the country of
such patent or patent application. 
 24.2     Any legal action related to this
Agreement will be conducted in San Francisco, California. 
 24.3     The prevailing
party in any suit related to this Agreement will be entitled to recover its reasonable attorneys’ fees in addition to its costs and necessary disbursements. 
 25.      Government Approval or Registration 
 25.1     If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, the Licensee will
assume all legal obligations to do so. The Licensee will notify The Regents if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. The Licensee will make all necessary filings
and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process. 

  
 34 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 26.      Compliance With Laws 

26.1     The Licensee shall comply with all applicable international, national, state, regional,
and local laws and regulations in performing its obligations hereunder and in its use, manufacture, Sale, or import of the Licensed Products, Licensed Services, or practice of the Licensed Method. The Licensee will observe all applicable United
States and foreign laws with respect to the transfer of Licensed Products and related technical data and the provision of Licensed Services to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and
the Export Administration Regulations. The Licensee shall manufacture Licensed Products and practice the Licensed Method in compliance with applicable government importation laws and regulations of a particular country for Licensed Products made
outside the particular country in which such Licensed Products are used, Sold, or otherwise exploited. 

27.      Force Majeure 

27.1     Except for the Licensee’s obligation to make any payments to The Regents
hereunder, the parties shall not be responsible for any failure to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous, including, but not limited to: accidents
(environmental, toxic spill, etc.); acts of nature; biological or nuclear incidents; casualties; earthquakes; fires; floods; governmental acts, orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and
materials; local, national, or state emergency; power failure and power outages; acts of terrorism; strike; and war. 
 27.2     Either party to this Agreement, however, will have the right to terminate this Agreement upon thirty (30) days’ prior written notice if either party is unable
to fulfill its 

  
 35 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
obligations under this Agreement due to any of the causes specified in Paragraph 27.1 for a period of one (1) year. 
 28.      Confidentiality 

28.1     The Licensee and The Regents will treat and maintain the other party’s proprietary
business, patent prosecution, software, engineering drawings, process and technical information, and other proprietary information, including the negotiated terms of this Agreement and any Progress Reports and royalty reports (“Proprietary
Information”) in confidence using at least the same degree of care as the receiving party uses to protect its own proprietary information of a like nature and will not disclose or, except as permitted herein, use such information from the date
of disclosure until five (5) years after the termination or expiration of this Agreement. This confidentiality obligation will apply to the information defined as “Data” under the Secrecy Agreement, and such Data will be treated as
Proprietary Information hereunder. 
 28.2     The Licensee and The Regents may use and
disclose Proprietary Information to their employees, agents, consultants, contractors, and, in the case of the Licensee, its sublicensees and potential investors and acquirors, provided that such parties are bound by a like duty of confidentiality
as that found in this Article 28. Notwithstanding anything to the contrary contained in this Agreement, The Regents may release this Agreement, including any terms contained herein, and information regarding royalty payments or other income received
in connection with this Agreement to the inventors, senior administrative officials employed by The Regents, and individual Regents upon their request. If such release is made, The Regents will request that such terms be kept in confidence in
accordance with the provisions of this Article 28. 

  
 36 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 28.3     All written Proprietary Information will
be labeled or marked confidential or proprietary. If the Proprietary Information is orally disclosed, it will be reduced to writing or some other physically tangible form, marked and labeled as confidential or proprietary by the disclosing party and
delivered to the receiving party within thirty (30) days after the oral disclosure. 

28.4     Nothing contained herein will in any way restrict or impair the right of the Licensee
or The Regents to use or disclose any Proprietary Information: 
  

	 	28.4.a	 that recipient can demonstrate by written records was previously known to it prior to its disclosure by the disclosing party;

  

	 	28.4.b	 that recipient can demonstrate by written records is now, or becomes in the future, public knowledge other than through acts or omissions of
recipient; 

  

	 	28.4.c	 that recipient can demonstrate by written records was lawfully obtained without restrictions on the recipient from sources independent of the
disclosing party; 

  

	 	28.4.d	 that The Regents is required to disclose pursuant to the California Public Records Act or other applicable law. 

The Licensee or The Regents may use or disclose Proprietary Information that is required to be disclosed (i) to a governmental
entity or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other governmental requirement or (ii) by law or regulation, provided that with respect to Proprietary Information other than the terms
of this Agreement the recipient uses reasonable efforts to give the party owning the Proprietary Information sufficient notice of such required disclosure to allow the party owning the Proprietary Information reasonable opportunity to object to, and
to take legal action to prevent, such disclosure. The Regents also may disclose the existence of this Agreement and the extent of the grant in Articles 2 (Grant) and 3 (Sublicenses) to a third party that inquires whether a

  
 37 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
license to the Patent Rights is available, but The Regents will not disclose the name of the Licensee, unless Licensee has already made such disclosure publicly. 

28.5     Upon termination of this Agreement, the Licensee and The Regents will destroy or return
any of the disclosing party’s Proprietary Information in its possession within thirty (30) days following the termination of this Agreement. The Licensee and The Regents will provide each other, within thirty (30) days following
termination, with written notice that such Proprietary Information has been returned or destroyed. Each party may, however, retain one copy of such Proprietary Information for archival purposes in non-working files. 

29.      Supply of Materials 

29.1     The Regents, through Inventors, will endeavor to transfer to Licensee the Materials
within one month from the date this Agreement is executed by The Regents. To the extent Licensee requires and requests additional samples from The Regents during the term hereof, and The Regents has such additional samples of the Materials in its
possession, The Regents will supply such additional samples to the Licensee. The Licensee will pay the actual handling and shipping costs for supplying initial samples and any additional samples provided to it. 

30.      Maintenance of Materials 

30.1     The Regents expressly reserves the right to transfer the Materials to educational and
non-profit institutions in each case only for educational and non-commercial research purposes. 

31.      Miscellaneous 

31.1     The headings of the several sections are inserted for convenience of reference only and
are not intended to affect the meaning or interpretation of this Agreement. 

  
 38 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 31.2     No amendment or modification of this
Agreement will be valid or binding upon the parties unless made in writing and signed on behalf of each party. 

31.3     This Agreement embodies the entire understanding of the parties and supersedes all
previous communications, representations, or understandings, whether oral or written, between the parties relating to the subject matter hereof. The Secrecy Agreement specified in the Recitals in this Agreement and dated April 21, 2003 is
hereby terminated. 
 31.4     If any of the provisions contained in this Agreement are
held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provisions hereof, and this Agreement shall be construed as if such invalid or illegal or unenforceable
provisions had never been contained herein. 
 31.5     No provisions of this Agreement
are intended or shall be construed to confer upon or give to any person or entity other than The Regents and the Licensee any rights, remedies, or other benefits under, or by reason of, this Agreement. 

31.6     In performing their respective duties under this Agreement, each of the parties will be
operating as an independent contractor. Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties hereto, or be construed to evidence the intention of the parties to establish any such
relationship. Neither party will have the power to bind the other party or incur obligations on the other party’s behalf without the other party’s prior written consent. 

 
 In witness whereof, both The Regents and the
Licensee have executed this Agreement, in duplicate originals, by their respective officers hereunto duly authorized, on the date and year hereinafter written. 

  
 39 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
  

									
	KALOBIOS INC.	 		 	 THE REGENTS OF THE

UNIVERSITY OF CALIFORNIA

					
	By:	 	 /s/ G. T. Yarranton
	 		 	By:	 	  /s/ Joel B. Kirschbaum

					
	Name:	 	 G. T. Yarranton
	 		 	         Name:	 	 Joel B. Kirschbaum

					
	Title:	 	   C.E.O.
	 		 	         Title:	 	 Director, OTM

					
	Date:	 	  6th April 2004
	 		 	         Date:	 	   4/6/04

  
 40 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 APPENDIX A 
 Inter-Institutional Agreement Between The Regents and MCWRF 
 UC Agreement Control
No. 2004-18-0030 

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 INTER-INSTITUTIONAL AGREEMENT 

for 

Method of and Composition for Immunization with the Pseudomonas V Antigen 

THIS AGREEMENT is effective December 28, 2003 by and between The MCW Research Foundation, Inc. (“MCWRF”), a wholly-owned
subsidiary of The Medical College of Wisconsin, Inc. (“MCW”), having an address at 8701 Watertown Plank Road, Milwaukee, WI 53226 and The Regents of the University of California (“The Regents”), a California corporation having
its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 and acting through its Office of Technology Management, University of California San Francisco, 185 Berry Street Suite 4603, San Francisco, CA 94107.

 BACKGROUND 

1.        Certain research performed at The University of California and at MCWRF resulted in the
development of inventions disclosed in UC Case Nos. SF99-038 and SF01-043 and MCWRF Case No. 1097 (the “Inventions”). 
 2.        The Inventions are covered by Patent Rights (as defined in this Agreement) and were developed by Dr. Dara Frank, Timothy Yahr and Robert Fritz at MCW
and Drs. Jeanine Wiener-Kronish, Teiji Sawa, and James Marks at the University of California, San Francisco (the “Inventors”). 
 3.        Effective December 28, 1998, The University of California and MCWRF entered an inter-institutional agreement as amended January 29, 2001 [UC
Agreement Control Number 99-19-0010] (“Previous Agreement”) whereby MCWRF administered the Inventions on behalf of both parties. 
 4.        It is now the mutual desire of the parties that the Previous Agreement be terminated, and subject to the provisions of this Agreement set forth below, the
Inventions be commercialized by The Regents on behalf of both parties and, to that end, MCWRF agrees not to grant to any person (other than The Regents) any right, title, or interest in and to the Inventions or the Patent Rights. 

5.        It is also the mutual desire of the parties that MCWRF continue to administer the Patent
Rights on behalf of both parties. 
 MCWRF and The Regents agree: 
 1.  DEFINITIONS 
 1.1 “Patent Rights” means all right,
title and interest in, to and under U.S. Provisional Patent Serial No. 06/109,952, entitled “Method of and Composition for Immunization with the Pseudomonas V Antigen”, Frank, Yahr, Sawa and Wiener-Kronish, inventors, filed
November 25, 1998 by MCWRF; U.S. Provisional Patent Serial No. 60/264,795, entitled “Single Chain Antibody Against PcrV”, Wiener-Kronish, Sawa, and Frank, inventors, filed January 29, 2001 by MCWRF; and any divisions,
continuations, or continuations-in-part (but only to the extent such continuations-in-part have inventors from both institutions) thereof; any corresponding foreign applications thereof; and any U.S. or joint foreign patents issued thereon or
reissues or extensions thereof, assigned by each inventor to his respective institution. 

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 1.2 “Net Revenues” means gross proceeds received by The Regents from the
licensing of Patent Rights, excluding any reimbursements for prosecution and maintenance of Patent Rights. 

1.3 “License Agreement” means any license agreement that is entered into by The Regents under this Agreement and grants to
a third party the right to make, have made, use, and/or sell products covered by Patent Rights, or any agreement granting an option for such a license. 
 1.4 “Licensee” means any licensee or optionee to a License Agreement. 

2.  PATENT PROSECUTION AND PROTECTION 
 2.1 MCWRF shall use commercially reasonable efforts to prepare and file appropriate United States patent applications covering the Inventions and shall provide to The Regents all serial numbers and
filing dates, together with copies of all the applications, including copies of all Patent Office Actions, responses and all other Patent Office communications. 
 2.2 MCWRF and The Reagents will each use their best efforts to assure that their respective Inventors fully cooperate in the preparation, filing, prosecution and maintenance of all patent
applications and patents covering the Inventions. 
 2.3 MCWRF shall, after consulting with The Regents and any Licensee,
and within eight months of any United States filing, make an election whether, when and in what countries, it wishes to file foreign patent applications. MCWRF shall notify The Regents, in writing, of its election regarding foreign filing. If
foreign patent applications are filed, MCWRF shall provide to The Regents all serial numbers and filing dates. MCWRF also shall provide to The Regents copies of foreign patent applications and patent office actions as The Regents may request in the
course of prosecution. 
 2.4 MCWRF shall record Assignments of domestic Patent Rights in the United States Patent and
Trademark Office and shall provide The Regents with a photocopy of each recorded Assignment. 
 2.5 Notwithstanding any
other provision of this Agreement, MCWRF shall not abandon the prosecution of any patent application (except for purposes of filing continuation or continuation-in-part applications) or the maintenance of any Patent Rights without prior written
notice to The Regents. 
 3.  LICENSING 
 3.1 Subject to Articles 2 and 4, MCWRF grants to The Regents the sole responsibility for licensing the Invention. 
 3.2 The Regents, with the assistance of MCWRF, shall diligently seek a Licensee for the commercial development of the Inventions and shall promptly provide to MCWRF copies of all License Agreements
relating to the Inventions. 

  
 2 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 3.3 Any License Agreement must include, but is not limited to, the following terms: a
license issue fee, an earned royalty, payment of patent costs by the Licensee, minimum annual royalties, diligence terms, indemnification of MCW, The Regents and sponsors of the research by Licensee, a disclaimer of any warranties on the part of The
Regents and a prohibition against the use of the name of The Medical College of Wisconsin and The Regents of the University of California or any campus thereof. License Agreements will further stipulate that no license or rights under any patents of
MCWRF or The Regents other than Patent Rights are granted or conferred by estoppel implication or otherwise, regardless of whether such patents are dominant or subordinate to the Patent Rights. 

3.4 The Regents shall not issue any paid-up licenses or assign Patent Rights to any third party without the prior written consent of
MCWRF. 
 3.5 License Agreements will expressly reserve to The Regents and MCW, the right to use the Inventions and
associated technology for educational and research purposes. 
 3.6 License Agreements shall stipulate that the Licensee
shall direct payments for previously unreimbursed and ongoing costs incurred in the patenting and maintenance of Patent Rights to MCWRF. 

4.  FINANCIAL TERMS 

4.1 MCWRF shall rebill The Regents for one-half of its unreimbursed costs incurred in the patenting and maintenance of Patent Rights.
The Regents shall reimburse MCWRF within sixty (60) days of receiving a bill from MCWRF. 
 4.2 Upon receipt of patent
expense reimbursements from a Licensee, MCWRF shall reimburse The Regents for any previous expenses rebilled and actually paid by The Regents. 
 4.3 On or before DECEMBER 1 of each year, The Regents shall distribute to MCWRF one-half of Net Revenues accrued during the most recently completed fiscal year (which ends June 30).

 4.4 Each party is solely responsible for calculating and distributing to its respective Inventors any share of Net
Revenues due in accordance with its respective patent policy. 
 5.  RECORDS AND REPORTS 

5.1 The Regents shall keep complete, true and accurate accounts of all expenses and of all proceeds received by it from each Licensee
and shall permit MCWRF to allow its own agents or a certified public accounting firm which is reasonably acceptable to The Regents to examine its books and records in order to verify the payments due or owing under this Agreement. MCWRF shall pay
the cost of each examination and shall request no more than one examination per year. 
 5.2 The Regents shall submit to
MCWRF, on request, a report, setting forth the status of all commercial development and licensing activity relating to the Inventions. 
 5.3 MCWRF shall keep complete, true and accurate accounts of all expenses related to costs incurred in the patenting and maintenance of Patent Rights and of all proceeds received by it

  
 3 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 
from each Licensee in this regard, and shall permit The Regents to allow its own agents or a certified public accounting firm which is reasonably acceptable to MCWRF to examine its books and
records in order to verify the payments due or owing under this Agreement. The Regents shall pay the cost of each examination and shall request no more than one examination per year. 

5.4 MCWRF shall submit to The Regents, on request, a report, setting forth the status of all patent activity relating to the
Inventions. 
 6.  PATENT INFRINGEMENT 
 6.1 In the event that patent administrators responsible for Patent Rights at The Regents or MCWRF learn of the substantial infringement of any patent covered by this agreement, the party who learned
of the infringement shall call the attention of the other party to the infringement and provide written evidence of infringement. The Regents shall, in cooperation with MCWRF use its best efforts to terminate infringement without litigation.

 6.2 If the efforts of the parties are not successful in abating the infringement within 90 days after the infringer has
been notified of the infringement, then The Regents may: 

	 	6.2.1	commence suit on its own account; or 

	 	6.2.2	permit an exclusive licensee to commence suit on its own account, or with The Regents; or 

	 	6.2.3	request that MCWRF join as a party plaintiff in a patent infringement litigation. 

 MCWRF has ninety (90) days to inform The Regents of its decision to join or not to join in such litigation. In no event may The Regents be joined in any suit without its prior written consent. If The
Regents chooses not to commence suit, or to allow an exclusive Licensee to do so, MCWRF may do so at its own election. 

6.3 Legal action to terminate infringement or to recover damages, as is decided upon under paragraph 6.2, will be at the full expense
of the party bringing suit and all amounts recovered thereby will belong to that party, provided, however, that legal action brought jointly by the parties and fully participated in by both parties will be at the joint expense of the parties (in
shares to be mutually agreed upon), and all recoveries will be shared jointly by them in direct proportion to the share of expense paid by each party. 
 6.4 Each party shall cooperate with the other in litigation proceedings instituted under this Agreement. The litigation will be controlled by the party bringing the suit, except that either party may
be represented by counsel of its choice in any suit brought by the other party. 
 7.  GOVERNING LAWS 

The scope and validity of any patent or patent application in Patent Rights are governed by the applicable laws of the
country of that patent or patent application. 

  
 4 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 8.  NOTICES 
 Any notice required or permitted to be given to the parties hereto is properly given if delivered, in writing, in person, sent by first-class certified mail, or by overnight carrier, to the following
addresses, or to such other addresses as may be designated in writing by the parties from time to time during the term of this Agreement: 
  

			
	To MCWRF:	  	MCW Research Foundation
		  	Medical College of Wisconsin
		  	8701 Watertown Plank Road
		  	Milwaukee, WI 53226
		  	Attn: Joseph Hill, Ph.D.
		
	To The Regents:	  	 Office of Technology Management

University of California San Francisco
 185 Berry
Street, Suite 4603

		  	 San Francisco, CA 94107

Attention: Director (Case Nos. SF99-038; SF01-043)

 9.  TERMINATION 
 9.1 This Agreement is in full force and effect from the effective date on page one and remains in effect for the life of the last-to-expire patent in Patent Rights, unless otherwise terminated by
operation of law or by acts of the parties in accordance with the terms of this Agreement. 
 9.2 If three (3) years
have passed from the effective date of this Agreement and no License Agreement is in effect or has been agreed upon as to all material financial terms, either party may terminate this Agreement for any reason upon at least 60 days’ written
notice to the other party, but in any event not less than 60 days prior to the date on which responses to any pending Patent Office actions need to be taken to preserve Patent Rights. After effective termination, The Regents and MCWRF will maintain
obligations identified in Article 10 (Confidentiality). 
 10. CONFIDENTIALITY 

10.1 Subject to The California Public Records Act, MCWRF and The Regents respectively shall hold the other party’s proprietary
business and patent prosecution information in confidence using at least the same degree of care as that party uses to protect its own proprietary information of a like nature. The disclosing party shall label or mark confidential, or as otherwise
appropriate, all proprietary information. If proprietary information is orally disclosed, the disclosing party shall reduce the proprietary information to writing or to some other physically tangible form and deliver it to the receiving party within
30 days of the oral disclosure, marked and labeled as set forth above. 

  
 5 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 10.2 Notwithstanding the foregoing, MCWRF and The Reagents will be free to publish
information relating to the Inventions in scientific journals. In furtherance of that publication right, MCWRF or The Reagents will supply the other, prior to its submission for publication, a copy of any manuscript relating to the invention that
lists authors from both The Medical College of Wisconsin and the University of California, San Francisco, to permit the other to evaluate such manuscript in order to determine whether it contains patentable subject matter relating to the Inventions.
At the request of the party to whom the manuscript is submitted, the submission of the manuscript for publication will be delayed up to thirty (30) days, in order to enable the preparation and filing of a patent application on any patentable
subject matter described in the manuscript. In implementation of the foregoing, within thirty (30) days after receipt of a manuscript intended for publication, the party receiving the manuscript will notify the other party whether or not a
patent application should be filed in accordance with the terms and conditions of this Agreement. If at the end of such thirty (30) day period, the parties are not able to agree to a mutually acceptable date for submission of the manuscript for
publication to enable the implementation of the decision to file a patent application, the party supplying the manuscript shall notify the other party of its intention to submit such manuscript for publication without the party’s approval.
Notwithstanding the foregoing, nothing in this Agreement in any way restricts or impairs the right of The Regents or MCWRF to use, disclose or otherwise deal with any information or data that: 

	 	10.2.1	recipient can demonstrate by written records was previously known to it; 

	 	10.2.2	is now, or becomes in the future, public knowledge other than through acts or omissions of recipient; 

	 	10.2.3	is lawfully obtained without restrictions by recipient from sources independent of the disclosing party; 

	 	10.2.4	was made independently without the use of proprietary information received hereunder; or 

	 	10.2.5	is required by law to be disclosed. 

 10.3 The confidentiality obligations of the recipient under these terms will remain in effect for five (5) years from the termination date of this Agreement. 

11. GENERAL 
 11.1 Use
of Names and Trademarks.  This Agreement does not confer any right to use any name, trade name, trademark, or other designation of either party to this Agreement (including contraction, abbreviation or simulation of any of the
foregoing) in advertising, publicity, or other promotional activities. The use of the name, “The Medical College of Wisconsin”, “The Regents of the University of California” or the name of any campus of the University of
California is prohibited. 
 11.2 No Waiver.  No waiver by either party hereto of any breach or default of
any of the covenants or agreements herein set forth may be deemed a waiver as to any subsequent and/or similar breach or default. 

  
 6 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 11.3 No Implied License.  This Agreement does not confer by
implication, estoppel, or otherwise any license or rights under any patents of either party other than the specific Patent Rights, regardless of whether such patents are dominant or subordinate to Patent Rights. 

11.4 Complete Agreement.  This Agreement constitutes the entire agreement, both written and oral, between the
parties, and all prior agreements respecting the subject matter of this Agreement, written or oral, expressed or implied, are canceled. The Previous Agreement is hereby terminated. 

The parties hereto have executed this Agreement in duplicate originals. 

									
	THE MCW RESEARCH FOUNDATION	 		 	 THE REGENTS OF THE UNIVERSITY OF
 CALIFORNIA

					
	By:	 	   /s/ William R. Hendee
	 		 	By:	 	   /s/ Joel B. Kirschbaum

		 	 (Signature)
	 		 		 	 (Signature)

 

									
	Name:	 	William R. Hendee, Ph.D.	 		 	Name:	 	   Joel B. Kirschbaum

		 	  (Please Print)
	 		 		 	  (Please Print)

 

									
	Title:	 	Executive Vice President	 		 	Title:	 	   Director – OTM

 

									
	Date:	 	   2-4-04
	 		 	Date:	 	   2/13/04

  
 7 

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 APPENDIX B 
 PATENT RIGHTS 
  

							
	    Case #        	 	
    Application      

    Number      
	 	Title	 	      
Filing Date    
	SF1999-038	 	US 60/109,952	 	 Method and Compositions for Immunization

with the Pseudomonas V Antigen
	 	11.25.98
	SF1999-038	 	US 60/126,794	 	Same as above	 	03.30.99
	SF1999-038	 	 US09/448,339

now US 6,309,651
 dated 10.30.01
	 	Same as above	 	11.23.99
	SF1999-038	 	PCT/US99/277769	 	Same as above	 	11.23.99
	SF1999-038	 	 US CIP
 09/770,916
	 	Same as above	 	01.26.01
	SF01-043	 	US 60/264,795	 	Single Chain Antibody Against PcrV	 	01.29.01
	SF01-043	 	PCT/US02-02382	 	 Method and Compositions for Immunization

with the Pseudomonas V Antigen
	 	01.25.02

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 APPENDIX C 
 MATERIALS 
  
  

Hybridoma: 
 [***] 

Pseudomonas strains: 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 AMENDMENT NO. 1 
 to the 
 License Agreement 

Effective April 6, 2004 
 Between 
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

and 
 KALOBIOS,
INC. 
  
 Effective June 17, 2004, THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA (“The Regents”) and KALOBIOS, INC. having a principal place of business at 3427 Hillview Ave., Suite 200, Palo Alto, CA 94304, (“Licensee”), agree as follows: 
 A. BACKGROUND 
  

	A.1	The Regents and Licensee are parties to a License Agreement effective April 6, 2004 (“Original Agreement”) covering docket numbers SF99-038, “Active
and Passive Immunization with the Pseudomonas V Antigen Protects Against Lung Injury”; and SF01-043, “Single Chain Antibody Against PcrV”. 

  

	A.2	The Regents and Licensee wish to amend the Original Agreement for the purpose of updating the list of materials specified in Appendix C of the Original Agreement.

 B. AMENDMENTS 
  

	B.1	Add the following to Appendix C, (MATERIALS): 

 “Polyclonal Antibody:  
 [***] 

Fab Fragments:  
 [***]” 
 All other terms and conditions of the Original Agreement will remain in full force
and effect. 

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 IN WITNESS WHEREOF, the parties hereto have executed these presents in duplicate by their
duly authorized officers or representatives as of the dates below: 
  

									
	KALOBIOS, INC.	 		 	 THE REGENTS OF THE UNIVERSITY
 OF CALIFORNIA

					
	By:	 	   /s/ Mark R. Alfraito
	 		 	By:	 	   /s/ James R.
Henderson

  

									
	Name:	 	   Mark R. Alfraito
	 		 	Name:	 	 James R. Henderson

 

									
	Title:	 	  President
	 		 	Title:	 	   Licensing Officer

 

									
	Date:	 	   6/17/04
	 		 	Date:	 	   6/21/04

  
 [***] CONFIDENTIAL PORTIONS
OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION.License Agreement

 Exhibit 10.17 
 LICENSE AGREEMENT 
 This License Agreement (“Agreement”)
is entered into by and between KaloBios Pharmaceuticals, Inc. (“KaloBios”), with offices at 3427 Hillview Ave, Suite 200, Palo Alto, CA, and Novartis International Pharmaceutical Ltd. (“NIP”), having its principal place of
business at Hamilton, Bermuda, on March 16, 2007 (“Effective Date”). NIP and its Affiliates shall be collectively referred to as “Novartis”. Accordingly, the Parties agree as follows: 

1. Definitions. 
 1.1 An
“Affiliate” means any Person who directly or indirectly controls or is controlled by or is under common control with a Party. For purposes of this definition, “control” or “controlled” means ownership directly or
through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any
other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity, or the
ability to cause the direction of the management or policies of a corporation or other entity. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum
percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence; provided that such foreign investor has the power to
direct the management and policies of such entity. For purposes of this Agreement, NIP and the Novartis Institute for Functional Genomics, Inc., dba the Genomics Institute of the Novartis Research Foundation (“GNF”) are each considered
Affiliates of the other. NIP shall be liable to KaloBios for all acts and omissions of its Affiliates as if performed by NIP under this Agreement. 
 1.2 “Collaboration Agreement” shall mean the Collaboration Agreement entered into by and among KaloBios, Novartis Pharma AG, and GNF on May 19, 2006 (as amended). 

1.3 “Completion Standard” shall mean the set of quantitative criteria, agreed upon by scientists from NIP or its
designated Affiliate and KaloBios in good faith, which represent reasonable metrics by which to evaluate NIP’s capability to successfully develop a Humaneered Antibody independent of KaloBios and to define the achievement of the Full Technology
Transfer (as defined in Section 3.3). The Completion Standard shall be deemed satisfied when NIP or its designated Affiliate has developed a Humaneered Antibody that has a binding affinity of at least 50% of that of the parent murine antibody
from which the Humaneered Antibody was developed. 
 1.4 “Control” shall mean the legal authority or right of a
Party to grant a license or sublicense of intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or
misappropriating the proprietary or trade secret information of a Third Party. 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 1.5 “Humaneering Technology” shall mean inventions (whether or not
patentable), processes, formulas, technology, reagents, protocols and know-how as set out in Exhibit A (as well as other such items that are not listed in Exhibit A but are used by KaloBios as of the Effective Date and are necessary to create such
engineered antibodies), Controlled or used by KaloBios as of the Effective Date comprising the method for creating engineered antibodies from Starting Antibodies. However, “Humaneering Technology” shall not include any commercially
available equipment, reagents or other materials. 
 1.6 “Humaneered Antibody” shall mean
(i) an engineered immunoglobulin protein or (ii) a fragment thereof less than the full-length antibody form (including, without limitation, Fv, Fab, and F(ab’)2, single-chain antibody, or other moiety which, in each case, includes at least one CDR (or fragment thereof) and is
capable of immunospecific binding); the development and manufacture of which incorporated Humaneering Technology. 
 1.7
“Novartis” shall mean NIP and its Affiliates, collectively (except as otherwise set forth in this Agreement). 

1.8 “Parties” shall mean KaloBios and NIP, and each individually shall be a “Party.” 

1.9 “Patents” shall mean any issued patent(s) and pending patent applications in any country, including, but not limited
to, all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all reissues, reexaminations, extensions and supplementary patent certificates thereof.

 1.10 “Person” shall mean any individual, corporation, partnership, association, joint-stock company, trust,
unincorporated organization or government or political subdivision thereof. 
 1.11 “Proprietary Information”
shall mean information relating to the disclosing Party’s business, including, without limitation, technical drawings, know-how, formulas, chemical and biological compositions, processes, ideas, and other technical, business, financial,
customer and product development plans, forecasts, strategies and information. Notwithstanding the foregoing, nothing will be considered “Proprietary Information” unless either (a) it is or was disclosed in tangible form and is
conspicuously marked “Confidential”, “Proprietary” or the like or (b) it is or was disclosed in non-tangible form and identified as confidential at the time of disclosure, except that the Humaneering Technology shall be
considered KaloBios’ Proprietary Information whether or not marked or identified as such. 
 1.12 “Proprietary
Rights” shall mean patent rights, copyrights, trade secret rights and all other intellectual property rights. Proprietary Rights shall include rights in KaloBios’ proprietary human antibody libraries, targets and technology, as
described in Exhibit A, including without limitation information, know-how, methods and processes relevant thereto, and all intellectual property rights related to any of the foregoing, as of the Effective Date or during the Term of this Agreement,
including without limitation any Patents controlled by KaloBios which are necessary and would be otherwise infringed to make, have made, use, sell, export and import a Humaneered Antibody. Such Patents include, for example, those patents and patent
applications listed on Exhibit B. 
  
 [***] CONFIDENTIAL PORTIONS OF
THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 2 

 1.13 “Starting Antibody” shall mean (i) an
immunoglobulin protein or (ii) a fragment thereof less than the full-length antibody form (including, without limitation, Fv, Fab, and F(ab’)2, single-chain antibody, or other moiety which, in each case, includes at least one CDR (or fragment thereof) and is
capable of immunospecific binding). 
 1.14 “Third Party” shall mean any Person other than a Party and its
Affiliates. 
 1.15 “Transfer Plan” shall mean a plan to achieve the Completion Standard. 

2. License; Restrictions. 

2.1 Subject to all the terms and limitations of this Agreement (including, without limitation, the Target Exclusion defined below),
KaloBios hereby grants Novartis a perpetual, worldwide, non-exclusive, non-sublicensable, non-transferable, royalty-free license under its Proprietary Rights in Humaneering Technology, solely to: (i) use Humaneering Technology for
Novartis’ internal research and development purposes; provided, however, that no V-segment libraries, Vheavy expression vectors, Vkappa expression vectors, or Vlambda expression vectors provided to Novartis by KaloBios may be possessed by or
reside at, nor may any other Humaneering Technology be practiced by, any Person that is not an Affiliate of NIP as of the Effective Date (and the foregoing shall not be licensed activity under this Section 2.1); and (ii) make, have made,
use, sell, offer to sell and import Humaneered Antibodies developed by Novartis. 
 2.2 KaloBios grants no license, by
implication or otherwise, except for the license expressly set forth in Section 2.1. Neither NIP nor its Affiliates shall (nor shall any of them enable or permit any Third Party to) directly or indirectly use or otherwise exploit any
Humaneering Technology under a “fee-for-service” type of arrangement (as that term is understood in the industry) for the benefit of any Third Party (excluding commercial, collaborative or other similar arrangements with a Third Party).

 2.3 As a material inducement for KaloBios to enter into this Agreement: 

(a) For the period beginning on the Effective Date and ending on the date five years from KaloBios’ receipt of all amounts due under
Section 6 below, neither NIP nor its Affiliates shall (nor shall any of them enable or permit any Third Party to) use Humaneering Technology or KaloBios Proprietary Information to directly or indirectly research, develop or manufacture (or
prepare to do so) any Humaneered Antibody against any of the targets set forth in Exhibit C, which are presently in KaloBios’ product pipeline (the “Target Exclusion”); and 

(b) For the period beginning on the Effective Date and ending on the date two years from KaloBios’ receipt of all amounts due under
Section 6 below, neither NIP nor its Affiliates shall (nor shall any of them enable or permit any Third Party to) develop or commercialize a Humaneered Antibody against a target of a Pre-Existing Project or a Committed Project (as those terms
are defined in the Collaboration Agreement) unless the milestone payments and royalties for that Target are paid as set forth in Sections 6.4 and 6.5 of the Collaboration Agreement or Novartis has exercised the Buy-Out Option set forth in
Section 6.7 of the Collaboration Agreement. 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 3 

 For the avoidance of doubt, the foregoing restrictions apply to all research and development activities that
use Humaneering Technology or KaloBios Proprietary Information. 
 3. Technology Transfer to NIP, or its Designated Affiliate.

 3.1 To enable Novartis to exercise the foregoing license, KaloBios will: (i) disclose and provide to NIP, or its
designated Affiliate, as soon as reasonably practicable following the Effective Date, the reagents and protocols as described in Exhibit A (the “Initial Technology Transfer”); and (ii) transfer the remainder of the tangible
embodiments of Humaneering Technology as described in Exhibit A and provide NIP, or its designated Affiliate, reasonable access to KaloBios scientists at a Novartis facility designated by NIP until NIP or its designated Affiliate has, at the
Novartis facility, developed one Humaneered Antibody that satisfies the Completion Standard (the “Full Technology Transfer”). NIP shall identify the target against which it plans to develop the Humaneered Antibody for purposes of
completing the Full Technology Transfer within two weeks of the Effective Date. 
 3.2 When KaloBios believes the Initial
Technology Transfer has been completed, KaloBios will notify NIP (or its designated Affiliate). NIP (or its designated Affiliate) will accept or reject completion of the Initial Technology Transfer in writing within thirty (30) calendar days
from receipt of such notice. NIP (or its designated Affiliate) may reject the Initial Technology Transfer only if the transfer failed in some material respect to meet the requirements therefor stated in Exhibit A and NIP’s (or its designated
Affiliate’s) notice to that effect includes a reasonably detailed description of such failure. Failure to give proper written notice of acceptance or rejection within the acceptance period will constitute acceptance. If the Initial Technology
Transfer is accepted, KaloBios will be conclusively presumed to have met its obligations with respect thereto and NIP shall pay KaloBios the fees as set forth in Section 6 below. 

3.3 NIP will notify KaloBios of the completion of the Full Technology Transfer. However, KaloBios will be conclusively presumed to have
met its obligations with respect thereto (it will be deemed accepted) on the earlier of the date: (i) when the TCC (described in Section 4 below) determines that the first Humaneered Antibody developed by NIP (or any Affiliate) in
conjunction with KaloBios’ services under this Section 3 materially conforms to the requirement set forth in the Completion Standard; or (ii) six (6) months following acceptance of the Initial Technology Transfer (subject to
Section 3.4 below). 
 3.4 KaloBios will extend the six (6) month time period in Section 3.3(ii) by one
(1) month for each month that the TCC determines KaloBios has failed to meet its diligence obligations as described in Section 4.3(v), until the Completion Standard has been satisfied. 

3.5 Upon request by NIP, KaloBios agrees to provide reasonable consulting services to NIP, or its designated Affiliate at commercially
reasonable rates during the period beginning at the completion of the Full Technology Transfer. 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 4 

 4. Governance. 
 4.1 The Parties will establish a Transfer Coordinating Committee (“TCC”), composed of two (2) representatives of KaloBios and two (2) representatives of NIP or its designated
Affiliate. 
 4.2 Within fifteen (15) days of the Effective Date, each Party will designate its initial members to serve on
the TCC. Each Party may replace its representatives on the TCC on written notice to the other Party. 
 4.3 The TCC shall have
the following responsibilities: (i) develop a mutually agreeable Transfer Plan within sixty (60) days of the Effective Date; (ii) monitor the schedules and progress of work pursuant to this Agreement; (iii) receive and submit
requests for information and/or assistance; (iv) generally oversee the day to day activities and relationship of the Parties pursuant to this Agreement; (v) documenting in outline format each month’s progress towards achievement of
the Completion Standard, where the TCC will specifically report in writing if KaloBios has failed to use commercially reasonable efforts to diligently transfer the Humaneering Technology as required herein; and (vi) report to NIP the
achievement of the Completion Standard. Notwithstanding anything to the contrary, the TCC is not authorized to amend, alter or extend this Agreement in any manner. 
 4.4 The TCC shall meet in person or by teleconference every four (4) weeks for the duration of the Initial and Full Technology Transfer (“Technology Transfer Period”) and quarterly
during the Disclosure Period. 
 4.5 In the event of a disagreement among the TCC members, the matter will be resolved in
accordance with Section 20; provided, however, that in the case of a disagreement with respect to Section 4.3(v), one of Novartis’ representatives (as designated by Novartis in advance as the chairperson of the TCC) shall be empowered
to cast two votes, as compared to one vote for each of the other three TCC members. 
 5. Intellectual Property. 

5.1 Ownership. As among the Parties, each Party and its respective Affiliates will be the sole owner of the intellectual property
rights in any invention of which only its employees and Third Party contractors are inventors, and each Party and its respective Affiliates will jointly own the intellectual property rights in all inventions of which its and another Party’s or
its respective Affiliates’ employees or contractors are joint inventors (“Joint IP”). Joint IP may be exploited and non-exclusively licensed to Third Parties by any Party without accounting to or further approval of the joint
owner(s). 
 5.2 Improvements. 
 (a) The license grant set forth in Section 2.1 shall include, at no additional charge to Novartis, any modification, extension, enhancement or improvement that is based on or derived from the
Humaneering Technology (“Improvements”), except Improvements created specifically in connection with a bona fide agreement with a Third Party, which KaloBios makes, conceives, or reduces to practice before the later of:
(i) thirty (30) months following completion of the Full Technology Transfer, or (ii) thirty-six (36) months following the Effective Date (the “Disclosure Period”). KaloBios shall provide reasonable consulting
services with respect to 
  
 [***] CONFIDENTIAL PORTIONS OF THIS
DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 5 

 
such Improvements as provided hereunder. Notwithstanding anything to the contrary, and for clarity, if KaloBios is acquired (whether in a merger, acquisition, change of control transaction, or
the like), no pre-existing intellectual property or technology of the acquiring Person shall be deemed an “Improvement.” For the avoidance of doubt, “Improvements” only include inventions, processes, formulas, technology,
reagents, protocols or know-how, and any corresponding intellectual property rights, relevant to developing Humaneered Antibodies from Starting Antibodies and do not include, for example, specific Humaneered Antibodies developed by Novartis under
its license. 
 (b) The Parties agree that nothing in this Agreement is intended to enable Novartis to prevent or restrict
KaloBios from practicing (at any time) its existing technology or any Improvements. Accordingly, Novartis hereby grants back to KaloBios a perpetual, worldwide, royalty-free, non-exclusive, non-sublicensable license, to make, have made, use, sell,
offer to sell and import Humaneered Antibodies using any and all Improvements made, conceived or reduced to practice during the Disclosure Period by Novartis, excluding (for clarity) specific Humaneered Antibodies developed by Novartis which are
potential therapeutic products of Novartis. For the avoidance of doubt, (i) the foregoing grant back shall be deemed to include, without limitation, any invention that (alone or together with others) tends to define, describe or surround any
part of the Humaneering Technology or any Proprietary Right licensed hereunder, and (ii) this Section 5.2(b) (unlike Section 5.2(c)) does not require Novartis to actually transfer technology or know-how to KaloBios. 

(c) The Parties agree to promptly disclose all Improvements to one another during the Disclosure Period. To assist in the transfer of
such Improvements, each Party will (I) be entitled to have a development engineer observe the operations of the others related to the Humaneering Technology for up to one (1) month per year during the Disclosure Period and (II) make its
personnel reasonably available during the Disclosure Period to provide the other Party with reasonable information and assistance concerning Improvements upon request. 
 6. Fees and Payment Terms. 
 6.1 NIP will pay KaloBios a non-refundable fee
of thirty million USD ($30,000,000). The payment will be made as follows: (i) [***] (ii) [***] (iii) [***]. 

6.2 All invoices shall conform to the extent reasonably practicable to the form of invoice contained in Exhibit D. All payments
due shall be paid in U.S. Dollars. All taxes related to any payments hereunder (except U.S. taxes on KaloBios’ net income) shall be paid by Novartis and are not deductible from the payments due KaloBios. If Novartis is required by law to deduct
or withhold any taxes from any amount payable to KaloBios hereunder, then the amount payable hereunder shall be increased so that after making all required deductions and/or withholdings (including deductions and withholdings applicable to any
additional amounts payable under this Section), KaloBios receives an amount equal to the amount it would have received had no such deductions or withholdings been made, and Novartis shall, after making full payment of any such tax, provide KaloBios
copies of tax receipts evidencing payment of such taxes. 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 6 

 7. Inspection While the license granted under Section 2.1 is in effect, KaloBios shall have the
right to appoint an internationally-recognized independent accounting firm reasonably acceptable to Novartis to inspect the relevant records and premises of Novartis to verify compliance with this Agreement. Before beginning its audit, the auditor
shall execute an undertaking acceptable to Novartis by which the auditor shall keep confidential all information reviewed during such audit. The auditor shall have the right to disclose to KaloBios its conclusions from the audit. Novartis shall make
its records and premises available for inspection by the auditor during regular business hours, upon receipt of reasonable advance notice from KaloBios, solely to verify Novartis’ compliance with this Agreement. Such inspection right shall not
be exercised more than once in any calendar year, unless the previous inspection revealed material non-compliance on the part of Novartis. KaloBios agrees to hold in strict confidence all information received and all information learned in the
course of any audit or inspection, except to the extent necessary for KaloBios to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order. KaloBios shall pay for
such inspections, as well as its own legal expenses associated with enforcing its rights with respect to any payments hereunder; except that in the event of Novartis’s noncompliance with any material term of this Agreement, Novartis shall pay
for such inspection. 
 8. Confidentiality. Except as allowed herein, each receiving Party will hold in confidence and not use or
disclose any Proprietary Information of the disclosing Party without the consent of the disclosing Party, and shall similarly bind its employees in writing. NIP may disclose KaloBios’ Proprietary Information to its Affiliates who have a need to
know such information for the purpose of exercising the rights and licenses granted hereunder. Each receiving Party shall not be obligated under this Section with respect to information such receiving Party can document (a) is or has become
readily publicly available without restriction through no fault of such receiving Party or its employees or agents, (b) is received without restriction from a Third Party lawfully in possession of such information and lawfully empowered to
disclose such information, (c) was rightfully in the possession of such receiving Party without restriction prior to its disclosure by the other Party, or (d) was independently developed by employees or consultants of such receiving Party
without access to such Proprietary Information. Each Party may disclose the other’s information that comprises Proprietary Information to the extent such disclosure is reasonably necessary in: (i) filing, prosecuting or defending
litigation; (ii) filing, prosecuting or defending patent rights that encompass the Humaneered Antibodies (but only to the extent that one Party gives its consent to another Party to make such disclosure, which consent shall not be unreasonably
withheld); or (iii) complying with applicable governmental regulations; provided, however, that if a Party is required to make any disclosure of the other Party’s secret or Proprietary Information, it will give reasonable advance notice to
the other Party of such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure confidential treatment of such Proprietary Information required to be disclosed. Upon any termination of this Agreement,
and upon request, each Party shall promptly return to the other all of the other Party’s Proprietary Information that is not the subject of an existing license granted hereunder. Each Party has the right to retain one copy of Proprietary
Information in their files for accounting and legal purposes. For eighteen (18) months from the Effective Date, neither GNF nor the Novartis Institutes for BioMedical Research (NIBR), an Affiliate of NIP, will, directly or indirectly, solicit
or induce any member of the KaloBios technical or scientific staff to leave the employ of KaloBios; the foregoing does not prohibit mass media 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 7 

 
“want ads” not specifically directed towards employees or consultants of a Party. Notwithstanding anything else, with respect to information disclosed by any Party outside of this
Agreement, this Agreement shall not expand, modify or otherwise supersede the terms and conditions of any non-disclosure or similar agreement entered into between KaloBios (on the one hand) and Novartis or any of their Affiliates (on the other
hand), which shall remain in full force and effect in accordance with its terms. 
 9. Patent Infringement and Enforcement Matters.

 9.1 Novartis shall mark, and shall ensure that its licensees and channel partners mark, products (or their containers or
labels) made, sold, or otherwise disposed of under this Agreement with the word “patent” or abbreviation “pat” and the applicable patent number(s), as KaloBios may notify Novartis from time to time if reasonably necessary to
protect KaloBios’ Proprietary Rights. 
 9.2 KaloBios may in its discretion take or not take whatever action it believes is
appropriate against any product or activity of any Third Party that may involve infringement or violation or an invalidity challenge of any Proprietary Right of KaloBios or Improvement to which KaloBios has a right to practice. 

9.3 Subject to Section 9.2, Novartis may in its discretion take or not take whatever action it believes is appropriate against any
product or activity of any Third Party that may involve infringement or violation or an invalidity challenge of any Proprietary Right relating to a Humaneered Antibody of Novartis. 

9.4 Notice. In the event that a Third Party at any time asserts a claim, or brings an action, suit or proceeding against a Party,
or any of its Affiliates or sublicensees, claiming infringement of such Third Party’s patent rights or unauthorized use or misappropriation of such Third Party’s know-how, based upon an assertion or claim arising out of any of the
activities taken in respect of Humaneering Technology or making, importing, use or sale of a Humaneered Antibody (such a claim, action, suit or proceeding, a “Third Party Infringement Claim”), such Party shall promptly notify the
other Party in writing of the claim or the commencement of such action, suit or proceeding, enclosing a copy of the claim and all papers served (to the extent not otherwise prohibited by law or contract). 

9.5 Defense of Third Party Infringement Claim. In the event of a Third Party Infringement Claim, and subject to the Indemnity
provisions set out in Section 12, the Party listed below shall assume control of the defense of such action, suit, proceeding or claim, and shall be entitled to settle any such claim against it in its sole discretion (but, for clarity, this
provision shall not give any Party the right to take any action or settle any claim on another Party’s behalf). 
 (a)
KaloBios, to the extent the Third Party Infringement Claim is directed against Humaneering Technology; and 
 (b) Novartis, to
the extent the Third Party Infringement Claim is directed against a Humaneered Antibody of Novartis. 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 8 

 The Party controlling such defense shall keep the other Party advised of the status of such
action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. 

10. Term and Termination. 

10.1 Term. This Agreement will remain in effect until the expiration of the last to expire of KaloBios patent rights that claim
Humaneering Technology, unless earlier terminated pursuant to Section 10.2. 
 10.2 Termination. If any Party should
materially breach this Agreement, a non-breaching Party may terminate this Agreement upon 60 days notice (30 days in the case of nonpayment) unless the breach is cured within the notice period. If the allegedly breaching party disputes that it has
materially breached the agreement, the non-breaching Party may not terminate the Agreement until after the completion of the Dispute resolution procedures set forth in Article 20 (i.e. related to the escalation within each Party and the Mediation).

 10.3 Effect of Termination. In the event of any termination of this Agreement, each Party will return to the other all
Proprietary Information of such other Party (and all copies and extracts thereof). In the event of termination pursuant to Section 10.2 and subject only to the remainder of this Section 10.3 and to Section 10.4 below, all rights and
licenses granted under this Agreement shall immediately terminate. Notwithstanding any termination or expiration, all rights and obligations concerning accrued payments shall survive. The terms of Sections 1, 2.2, 2.3, 5.1, 5.2(b), 7-8, 9.1, 10.3,
10.4, 11-14 and 16-21 shall survive expiration or termination of this Agreement. Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain available. 

10.4 Optional Post-Termination Rights. 
 (a) In the event of termination by Novartis pursuant to Section 10.2, all rights and licenses granted to Novartis under this Agreement shall become irrevocable: (i) if Novartis notifies KaloBios
within thirty (30) days of such termination of its intent to exercise the rights under this Section 10.4(a); (ii) if Novartis promptly pays or has paid KaloBios in full any and all amounts that are contemplated to be paid to KaloBios
pursuant to Section 6 at the time of such termination; and (iii) subject to compliance with the surviving sections set forth in Section 10.3 above. 
 (b) In the event of any termination of this Agreement by KaloBios pursuant to Section 10.2, Novartis may continue to make, have made, use, sell, offer to sell and import Humaneered Antibodies
existing on the effective date of termination, subject to: (i) NIP notifying KaloBios within thirty (30) days of such termination of its intent to exercise the rights under this Section 10.4(b) (which notice shall include a reasonably
detailed description of all Humaneered Antibodies existing at that time, and the clinical or pre-clinical stage of development for each); (ii) Novartis’ compliance with all surviving provisions of this Agreement; and (iii) Novartis
paying KaloBios royalties and milestones on all such Humaneered Antibodies as if they were “Products” under the Collaboration Agreement (i.e. all amounts set forth in Sections 6.4 (Milestones) and 6.5 (Royalties) of the Collaboration
Agreement, reading 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT
REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 9 

 
the term “Product” in such sections of the Collaboration Agreement as “Humaneered Antibody” for that purpose). Section 7 (Payments; Records) of the Collaboration
Agreement shall apply with respect to all amounts owed to KaloBios under this Section 10.4(b). If NIP or any of its Affiliates should materially breach this Agreement while this Section 10.4(b) is in effect, KaloBios may terminate all
rights granted under this Section upon 60 days notice (30 days in the case of nonpayment) unless the breach is cured within the notice period. 
 10.5 No Termination Payments. No Party shall incur any liability whatsoever for any damage, loss or expenses of any kind suffered or incurred by the other arising from or incident to any
termination of this Agreement (or any part thereof) by such Party which complies with the terms of the Agreement whether or not such Party is aware of any such damage, loss or expenses. 
 11. Limited Liability. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, EXCEPT FOR A PARTY’S BREACH OF CONFIDENTIALITY OR NIP’S OR ITS AFFILIATE’S BREACH OF SECTION 2.3,
NO PARTY SHALL BE LIABLE OR OBLIGATED WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT OR UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR: (I) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES OR LOST PROFITS; OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES. MOREOVER, KALOBIOS SHALL NOT BE LIABLE UNDER ANY THEORY FOR ANY AMOUNTS IN EXCESS IN THE AGGREGATE OF THE FEES PAID TO IT HEREUNDER. 

12. Indemnity. 
 12.1
KaloBios will defend, indemnify and hold Novartis harmless against any claims, damages, settlements and expenses (including attorneys’ fees) in respect of injury (including death) to any persons or damage to any real or tangible property
arising out of (a) the negligence or willful misconduct of KaloBios in the performance of the services under Section 3 of this Agreement, and (b) a Third Party claim against Novartis resulting from a breach of the representations and
warranties set forth in Section 14.2; provided KaloBios shall not be liable for nor be required to indemnify Novartis in regard to any injury or damage caused by any negligence or willful misconduct on the part of Novartis’ development,
manufacture, use, sale, storage or handling of Humaneered Antibodies under this Agreement. This Section 12.1 states KaloBios’ entire obligation and Novartis’ sole remedy with respect to infringement of Third Party intellectual
property rights, and KaloBios’ liability under this Section shall be limited to a maximum of [***]. 
 12.2 Novartis will
defend, indemnify and hold KaloBios and its Affiliates harmless against any claims, damages, settlements and expenses (including attorneys’ fees) arising out of or relating to Novartis’s exercise of the rights granted under this Agreement
(including, without limitation, the manufacturing and clinical exploitation of Humaneering Technology or Humaneered Antibodies). 
 12.3 The indemnification obligations under this Section shall be conditioned upon the indemnified Party (a) promptly notifying the indemnifying Party of such claim; (b) turning over 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 10 

 
to the indemnifying Party sole control with respect to the defense and settlement of such claim; and (c) fully cooperating with the indemnifying Party in the defense and settlement thereof,
provided the indemnifying Party reimburses it for all out-of-pocket expenses incurred in providing such cooperation. An indemnified Party’s failure to promptly notify the indemnifying Party shall not relieve the indemnifying Party of its
obligations under this Section 12 except to the extent that the indemnifying Party can demonstrate damages attributable to such failure. 

13. Export Control. Each Party shall comply with all applicable export laws, restrictions, and regulations of any United States or foreign agency
or authority and will not export or re-export, or allow or authorize the export or re-export of, any Humaneered Antibody, technology or information it obtains or learns pursuant to this Agreement in violation of any such laws, restrictions or
regulations. 
 14. Warranty and Disclaimer. 
 14.1 Each Party represents and warrants to the other Party that: (i) it has full corporate power and authority to enter into and perform this Agreement, and (ii) neither its entering nor
performing this Agreement will violate any right of or breach any obligation to any Third Party under any agreement or arrangement between such Party and the Third Party. 
 14.2 KaloBios represents and warrants to Novartis that: (i) except with respect to the expression of immunoglobulins, the methods and libraries used in Humaneering Technology, if practiced in Europe
or North America, do not infringe any Third Party intellectual property right known to KaloBios as of the Effective Date; and (ii) KaloBios has not received written notice from any Third Party of infringement of a Third Party patent right by
the making, importing, use or sale of Humaneering Technology or a Humaneered Antibody. 
 14.3 OTHERWISE, NO PARTY MAKES ANY
WARRANTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF AND EACH PARTY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. KALOBIOS MAKES
NO WARRANTY REGARDING THE RESULTS OF USE OR SAFETY OR EFFICACY OF ANY ANTIBODY OR OTHER MATTER. 
 15. Publicity. The Parties will agree
upon the timing and content of any initial press release or other public communications relating to this Agreement and the transactions contemplated herein. 
 15.1 Except to the extent already disclosed in that initial press release or other public communication, no public announcement concerning the existence or the terms of this Agreement or concerning the
transactions described herein shall be made, either directly or indirectly, by any Party, except as may be legally required by applicable laws, regulations, or judicial order, without first obtaining the approval of the other Party and agreement
upon the nature, text, and timing of such announcement. 
 15.2 The Party desiring to make any such public announcement shall
provide the other Party with a written copy of the proposed announcement in sufficient time (no less than thirty (30) days) prior to public release to allow such other Party to comment upon such announcement prior to public release. 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 11 

 16. Relationship of the Parties. Notwithstanding any provision hereof, for all purposes of this
Agreement each Party shall be and act as an independent contractor and not as partner, joint venturer, or agent of the other and shall not bind nor attempt to bind the other to any contract. 
 17. Assignment. No Party shall have any right or ability to assign or transfer any obligations or benefits under this Agreement without the written consent of the other Party (and any unauthorized
purported assignment will be void), except that a Party may assign and transfer this Agreement and its rights and obligations hereunder to any Affiliate or to any Third Party who succeeds to all or substantially all its business or assets. This
Agreement will be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. 
 18. Notice. All
notices under this Agreement shall be in writing, and shall be deemed given when personally delivered or three days after being sent by prepaid certified or registered U.S. mail to the address of the Party to be noticed as set forth herein or such
other address as such Party last provided to the other by written notice. Any such notice or communication may also be delivered by hand or by facsimile to the appropriate addressee. Notices shall be sent: 

 

			
	If to KaloBios, to:	  	KaloBios Pharmaceuticals, Inc.
		  	Attn: Mark Alfenito
		  	3427 Hillview Ave, Suite 200
		  	Palo Alto, CA
		  	Fax: (650) 843-1896
		
	If to NIP, to:	  	Novartis International Pharmaceutical Ltd.
		  	Attn: President
		  	 P.O. Box HM 2899
 Hamilton
HM LX
 BERMUDA

		  	Fax: (441) 296-5083
		
	With a copy to:	  	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
		  	220 Massachusetts Avenue
		  	Cambridge, Massachusetts 02139
		  	Attention: Legal Dept.
		  	Fax: (617) 871-3354
		
		  	Genomics Institute of the Novartis Research Foundation
		  	Attn: General Counsel
		  	10675 John Jay Hopkins Drive
		  	San Diego, CA 92121
		  	Fax: (858) 812-1981

 19. Miscellaneous. The failure of any Party to enforce its rights under this Agreement at any time for any period
shall not be construed as a waiver of such rights. No changes or 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 12 

 
modifications or waivers are to be made to this Agreement unless evidenced in writing and signed by both Parties. In the event that any provision of this Agreement shall be determined to be
illegal or unenforceable, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. In any action or proceeding to enforce rights under this
Agreement, the prevailing Party will be entitled to recover costs and attorneys fees. No liability or loss of rights hereunder shall result to any Party from delay or failure in performance (other than payment) caused by circumstances beyond the
reasonable control of the Party affected thereby. 
 20. Dispute Resolution. 

20.1 The Parties recognize that disputes as to certain matters relating to either Party’s rights and/or obligations hereunder may
arise from time to time. It is the objective of the Parties to establish procedures to facilitate, if at all possible, the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. Any dispute arising
between the Parties relating to, arising out of or in any way connected with the Agreement or any term or condition hereof, whether before or after termination of the Agreement, including but not limited to: (1) the performance by either Party
of its obligations hereunder; (2) the rights of either Party hereunder; and (3) any allegedly improper actions of either Party that may be deemed to be intentionally and/or negligently tortious conduct (a “Dispute”), will be
resolved as set forth in this Section 20. 
 20.2 Any Dispute shall first be brought to the attention of the Chief
Scientific Officers of the Parties (or their respective designees, who shall have sufficient authority to ensure acceptance and execution of any Dispute resolution that is reached). 

20.3 If the Chief Scientific Officers (or their designees) are unable to resolve such Dispute within forty-five (45) days of the
first presentation of such dispute to the Chief Scientific Officer, then such Dispute shall be referred to the Chief Executive Officers of each of the Parties (or their respective designees, who shall have sufficient authority to ensure acceptance
and execution of any Dispute resolution that is reached), who shall use their good faith efforts to mutually agree upon the proper resolution of the Dispute or an appropriate plan of action to resolve the Dispute. 

20.4 If any dispute is not resolved by the Chief Executive Officers of the Parties (or their designees) within thirty (30) business
days after such dispute is referred to them, or such longer period as the Chief Executive Officers (or their respective designees) may collectively agree, then any Party shall have the right to request non-binding mediation for such dispute
(“Mediation”). The Mediation shall be administered by the American Arbitration Association in accordance with its commercial mediation rules. Unless otherwise mutually agreed upon by the Parties, the Mediation proceedings shall be
conducted in San Diego. The Parties agree that they shall share equally the cost of the Mediation, including filing and hearing fees, and the cost of the mediator(s). Each Party shall have the right, at its own expense, to be represented by counsel
in such a proceeding. Each Party shall use commercially reasonable efforts to commence Mediation proceedings within thirty (30) days subsequent to the initial written request for such Mediation. If any unresolved matter is not resolved
following such Mediation, or in the event that such Mediation is not concluded: (i) within sixty (60) days subsequent to the first meeting of 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 13 

 
the Parties in connection with such Mediation; or (ii) within ninety (90) days subsequent to the initial written request for such Mediation, then either Party shall have the right to
take such other action as is permitted under the relevant laws, taking into account the provisions of Section 21 (Governing Law and Venue). Notwithstanding the foregoing, nothing in this Section 20 shall limit a Party’s right to seek
injunctive or other equitable relief in court at any time. 
 21. Governing Law and Venue. This Agreement shall governed by the laws of
the state of California, without regard to conflicts of law principles. The Parties agree for all controversies under this Agreement, unless otherwise provided in Section 20, the State and Federal Courts of California shall have exclusive
jurisdiction. 
 [Signature page follows] 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 14 

 
			
	KALOBIOS PHARMACEUTICALS, INC
		
	By	 	 /s/ David W. Pritchard

	Name:	 	 David W. Pritchard

	Title	 	 Chief Executive Officer

		 	 KaloBios Pharmaceuticals, Inc.

	
	NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
		
	By	 	 /s/ Emil Brock

	Name:	 	 Emil Brock

	Title:	 	 Member of the Board

		
	By	 	 /s/ Robert L. Thompson

	Name:	 	 Robert L. Thompson

	Title:	 	 Member of the Board

  
 [***] CONFIDENTIAL PORTIONS OF THIS
DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 15 

 EXHIBIT A 
 [***] 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 EXHIBIT B 
 [***] 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 EXHIBIT C 
 [***] 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 Exhibit D 
 Form of Invoice 
  

			
	Sender’s Logo	  	INVOICE
		
		  	INVOICE DATE:
	Street	  	[Month] [day] 200x
	Town, Country	  	
	Phone and Fax Nr.	  	INVOICE No.: XXX

  

			
	 Bill to: 
	  	For:
	 Novartis International Pharmaceutical Ltd.

“Hurst Holme”, 12 Trott Road

Att. Mr. Emil Bock/ Ms. Wendy Wiseman

P.O Box HM 2899
 Hamilton, HM LX
 Bermuda

and via fax, facsimile No. +1 441 296 5083
	  	

  

					
	 DESCRIPTION
	  	AMOUNT (USD)	 
	 	  	US$000’000	 
	 (milestone payment for event Y, according to paragraph XY of agreement ZZZ dated...)
	  			
		
	 Novartis Contract Code
	  			
		
	 Please specify the event for which the invoice is due
	  			
		
	 Please remit by wire transfer to:
	  			
		
	 Receiving Bank -
	  			
	 Swift Code -
	  			
	 ABA Number -
	  			
	 Credit Account -
	  			
	 Beneficiary -
	  			
		  	  
	  
	 
	 TOTAL
	  	 	000’000	  
		  	  
	  
	 

 If you have any questions concerning this invoice, contact ......... 

or e-mail to ......... 
 VAT - Reg. No.
Xxxxxxxxxx (if partner has one) 
 Best regards, 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]